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Abstract 
Background: Pericytes represent a heterogeneous and abundant population of cells that can contribute 
to tissue regeneration in vivo and can be expanded in vitro to be used for regenerative medicine 
applications. However, ageing can blunt the regenerative potential of cells. We have previously derived 
cardiac pericytes (CPs) from myocardial leftovers of new-born patients operated for correction of 
congenital heart disease (CHD). A high number of patients reach the adult life and still needs therapeutic 
intervention.  
Aims: To investigate if adult heart contains a population of CPs and if so, whether ageing affects CPs 
phenotype and functional properties in vitro.  
Methods: We isolated and expanded to passage 5 cells from newborn (nCPs, N=3, age<30 days) and 
adult (aCPs, N=3, age 14 to 54 years) patients. Antigenic profile, growth rate, secretome, angiogenic 
activity and vascular plasticity were investigated and compared. 
Results: After in vitro expansion, both aCPs and nCPs were positive for CD34, NG2, PDGFRβ but negative 
for CD146 and endothelial and vascular smooth muscle cell (VSMC) markers. Cells also express similar 
levels of stemness markers, were endowed with the same average growth rate and secreted similar 
amounts of pro-angiogenic factors: VEGF, Ang-1, and Ang-2. Only aCPs cells significantly increased the 
formation of tubular networks by cardiac endothelial cells (ECs), while for nCPs neither secretome nor 
cells showed this capacity when co-cultured with the ECs. Hence further investigation with increased 
sample number is required for angiogenic capacity assessment. Finally, all CPs were able to express 
VSMC markers upon exposure to differentiation media. 
Conclusion: Our results show for the first time that within adult human heart there is a population of 
CPs previously only reported for newborn hearts. These aCPs present similar phenotypic and functional 
properties to nCPs. 
 
Keywords: Cardiac pericytes, ageing, vascular smooth muscle cells 
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Chapter 1: Introduction 
 
Chapter 1 Introduction 
 Cardiovascular system organization and heart action 
The cardiovascular system is composed of the heart that generates hydrostatic pressure and pumps the 
blood through the network of vessels to all parts of the body. Blood is vital fluid composed of plasma, 
which carries, nutrients, hormones, dissolved gasses, metabolites as well as, circulating white cells, red 
cells and platelets (Klabunde, 2012). 
The heart is anatomically separated from the surrounding tissue by the pericardial sac, which is 
composed of an the inner serous pericardium and outer fibrous pericardium. The fibrous pericardium is 
attached to the walls of the interior of the pericardial cavity and provides protection against mechanical 
damage. Meanwhile, the serous pericardium has a pericardial cavity, which contains the fluid that 
absorbs shock and lubricates the heart exterior during cardiac activity. This cavity is located between the 
parietal layer that is merged to the fibrous pericardium and the visceral layer that is merged to the 
exterior of the heart wall (Moore, et al., 2013). 
The heart is composed of three main layers of tissue: the epicardium, myocardium, and the endocardium 
(see Figure 1). The epicardium is the outer layer that is fused to the visceral layer of the pericardium and 
covers the myocardium. The endocardium is composed of an endothelial cells (ECs) lining that covers 
the interior of the heart. The myocardium is a layer of cardiac muscles comprising of cardiomyocytes, 
which provides the contractile forces to constrict the heart chamber and pump blood (Klabunde, 2012). 
Cardiac muscle cells have a high metabolic requirement, which is fulfilled by a network of coronary 
vessels that penetrate heart tissues and feed residential cells. Sufficient blood flow within the cardiac 
vessels is key to the maintenance of heart rate, generated by intrinsic myogenic activity (Moore, et al., 
2013).  
 
Heart activity, i.e. the contraction and relaxation of cardiac muscle tissues during systole and diastole, is 
dictated by pacemaker cells located in the sinoatrial (SA) node of the right atrium (RA). Cardiomyocytes 
located in SA node do not require extrinsic stimulus as they possess own myogenic activity. Electric 
impulse is generated at the SA node, it then propagates through both atria until it reaches the 
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atrioventricular (AV) node located in the lower region of interatrial septum (Moore, et al., 2013). This 
region contains specialized cells that delay electrical impulses which coordinate contraction during the 
cardiac cycle. When an electrical impulse propagates through this region, these cardiac cells delay 
electrical impulse by as much as 0.12 seconds so that both atria contract synchronically and all blood is 
transferred to (Klabunde, 2012). The electrical impulse is then conducted through specialized fibres 
called the Bundle of His as it infiltrates the upper region of the ventricular septum. The bundle of His 
approaches the apex of the heart through the septum, where the signal splits to the left and right, and 
then splitting further into small conduction channels called Purkinje fibres (Kennedy, et al., 2016). The 
action potential causes ventricles to contract, pushing blood from the right ventricle (RV) into the 
pulmonary artery (PA) and the blood from the left ventricle (LV) into the aorta (Moore, et al., 2013). 
 
The heart pumps blood through a network of blood vessels, called the circulatory system, which can be 
separated into two portions. One of which maintains systemic circulation by pumping oxygenated blood 
from left chambers of the heart to all tissues around the body via aorta and returning deoxygenated 
blood back to the RA heart via inferior and superior vena caves (IVC and SVC). The other half maintains 
pulmonary circulation, which pumps deoxygenated blood from RV via PA to the lungs, and returning 
oxygenated blood via the left and right pulmonary veins to LA (Kennedy, et al., 2016) (Moore, et al., 
2013). 
Efferent blood vessels are called arteries, they branch out into small vessels called capillaries that 
infiltrate tissue, which are connected to blood returning vessels called veins. This flow is driven by the 
hydrostatic pressure that results when the ventricles contract, which must be maintained throughout 
the cardiac cycle. To do so, the ventricular contrition takes advantage of the elasticity of aorta and PA. 
These vessels have a thick layer of smooth muscle cells (SMCs), which generate a recoil capacity that 
allows blood to push down the arteries, when ventricles are not contracted (Kennedy, et al., 2016) 
(Moore, et al., 2013). To perform this, ventricles must contract enough to create sufficient hydrostatic 
pressure to push the fluid through the blood vessels to be returned back to the heart (Moore, et al., 
2013) (reviewed in (Lacolley, et al., 2017). 
Both arteries and veins share structure characteristics and are composed of three main layers of tissue: 
tunica adventitia, tunica media, and tunica intima. The tunica intima has an endothelium, which 
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separates lumen, a layer of connective tissue and a basement membrane composed of elastic fibres that 
resist expansion due to hydrostatic pressure (Moore, et al., 2013) (reviewed in (Lacolley, et al., 2017)). 
Under physiological , ECs composing vascular endothelium, are involved in vascular tone and 
homeostasis  (Ley & Reutershan, 2006). Under pathological circumstances ECs regulate vessel 
permeability and recruitment of white blood cells from the circulation to local tissue (Minshall & Malik, 
2006). The tunica adventitia is formed of collagen fibres, which provides physical protection and rigidity 
whilst anchoring to surrounding tissues (reviewed in (Bazzoni & Dejana, 2004)).  
Despite similarities, arteries and veins have anatomical differences that allow for specialization. In 
arteries the tunica media is composed of a thick layer of SMCs, while in veins, there is a thin layer of 
SMCs. (Tucker & Bhimji, 2017). Veins carry blood away from the tissue, even against the gravitational 
force, straight to the atrium of the heart. The contraction of skeletal muscles located around the vein 
can help push blood pass internal valves preventing backward flow (Moore, et al., 2013). 
Capillaries are the smallest vessels, composed of ECs, surrounded by pericytes. Arterial circulation is 
connected to venular circulation through a capillary network that acts as a site of nutrient, gas, and waste 
product exchange. ECs perform transport of nutrients and gasses through both pinocytosis passive 
diffusion (reviewed in (Hislop, 2002)).  
 
The heart requires a continuous blood supply because cardiomyocytes cannot tolerate hypoxia well. 
Consequently, cardiac tissues extract oxygen from the blood more readily than resting skeletal muscles 
and the intestine for instance. Blood supply is provided by two coronary arteries, which branch off from 
the aorta into a vascular bed that penetrates myocardial tissues. (Klabunde, 2012). As a consequence of 
the high demand for cardiac tissue even short-term restriction of the blood supply results in ischemia 
and rapid cell death followed by impaired contraction of the heart ventricles. Accumulatively, this can 
greatly reduce the pumping potential of the heart (Klabunde, 2012).  
Normally in an event of vessel occlusion, collateral circulation would provide an alternative blood supply. 
During coronary artery disease, the occlusion of the artery increases tangential shear stress experienced 
by the endothelium (Seiler, et al., 2013) (reviewed in (Zimarino, et al., 2014)). This stimulates 
arteriogenesis and the pre-existing collateral vessels within the heart gain in size and to bypass the  
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Figure 1: External anterior heart anatomy with coronary vessel positions and structure of the heart 
wall.  
A: Anatomical structure of the heart with major coronary arteries. Small arrows indicate the direction of 
blood. Color corresponds to oxygen saturation (Red-oxygenated, Blue-deoxygenated.)  
B: Structure of the heart wall and the organization of tissues.  
Right atrium (RA), right ventricle (RV), left atrium (LA), left ventricle (LV), aorta (AO), pulmonary artery 
(PA), superior vena cave (SVC), inferior vena cave (IVC). 
blockage (reviewed in (Pascal , et al., 2013)). Despite this, collateral circulation is not enough to fully 
compensate for the occlusion. In fact, even if one artery becomes obstructed, physiological function of 
cardiac tissue becomes impaired drastically. Additionally, the surgical reopening of obstructed coronary 
artery exacerbated condition by a phenomenon known as reperfusion injury which causes additional 
stress. The ischaemic-reperfusion injury damages cardiomyocytes and promotes ventricular arrhythmia 
which can even progress to HF (reviewed in (Hausenloy & Yellon, 2013) (Neri, et al., 2017)). This 
promotes the local cells to acquire senescent phenotype and can further impair tissue homeostasis 
(reviewed in (Rota, et al., 2015). 
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Despite his the complex vascular bed that developed as a consequence of ischemia can still partially 
regress if the shear stress stimulus ceases (reviewed in (Pascal , et al., 2013)). 
 
Cardiovascular diseases (CVD) is a generic term describing conditions associated with cardiac and 
vascular pathologies, which can be both congenital or acquired. Examples of common cardiovascular 
disease include ischaemic heart disease, rheumatic heart disease, heart arrhythmia and congenital heart 
disease (CHD) (Mendis, et al., 2011). The treatment of CVDs, in general, include drugs such as 
anticoagulants, beta-blockers, calcium ion (Ca²⁺) channel blockers, and angiotensin-converting-enzyme 
inhibitors. While it is estimated that 90% of CVDs are preventable, by modulating diet and life-style, their 
complications are often severe or even life threatening (reviewed by (McGill, et al., 2008)). Heart failure 
(HF) can developed as a severe complication following prolonged CVD. It is a life-threatening condition 
presented as an inability of the heart to pump blood around the body. There are multiple risk factors 
determining the possibility of progression from CVD to HF as both underlying genetics and environment 
play a significant role. In 2014, it was estimated that CVDs are responsible for 70% of HF cases (Mitchell, 
et al., 2014), and so far it can only be effectively treated through heat transplantation (Klabunde, 2012). 
 
CHDs is a severe congenital condition and includes many birth defects affecting the anatomical structure 
of newborn’s heart (see Figure 2). With multiple levels of complexity, CHDs have consequently various 
approaches directed towards symptom elimination and improvement of organ function. Most common 
CHDs include ventricular septal defect (VSD), tetralogy of Fallot (TOF), coarctation of the aorta, and 
patent ductus arteriosus (reviewed in (Klouda, et al., 2014)).  
As birth defect, CHD affect nearly 1% of newborns in the UK (NHS, 2015). Patients with CHD remain at 
life-long risk of developing HF with more than 50% of individuals progressing to HF by the age of 30 
(Kambiz Norozi, et al., 2006). Amongst all possible CHD, the TOF is mostly associated with HF in early 
adulthood. By the age of 50, nearly 80% of patients with TOF that had undergone corrective surgery in 
childhood, develop HF (Kambiz Norozi, et al., 2006).  
Newborns presented with TOF require surgical intervention shortly after birth (reviewed in (Fuller, 
2014)). The complexity of pathology combined with the weakness of newborn decreases the chance of 
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condition elimination and full recovery. Newborns are often too weak to undergo prolonged corrective 
surgery directly after birth, and instead, palliative surgery can be used to alleviate symptoms of TOF 
despite these effects being only transient (Kempny, et al., 2017) (NHS, 2015).  
Corrective surgery also does not provide a life-long solution as graft, currently used in therapies, cannot 
sustain patients tissue growth and tend to deteriorate over time (Avolio, et al., 2015(c)), therefore, 
patients remain subjected to repetitive surgical operation over years (Said & Burkhart, 2014). In more 
severe cases patients require the same corrective surgery multiple times, to replace deteriorating grafts, 
affected by fibrosis and calcification, which cause tissue remodelling. (Avolio, et al., 2015(c)). 
Furthermore progressive loss of functions is intricate to the ability of grafts to trigger a thrombotic event 
(reviewed in (Klouda, et al., 2014)). 
Due to increase in the rate of survival of children born with CHD, the current number of adults with CHD 
outnumber the children with the same condition (Kempny, et al., 2017). These affected adults remain 
permanently at risk of morbidity and mortality due to progression to HF ( Qureshi & Benson, 2012) and 
the only resolution in case of HF is heart transplantation, which however is not the ultimate option at 
any mean (reviewed in (Mangini, et al., 2015)).  
Shortage of donor organ is the major limiting factor and combined with high cost, the risk of 
complications associated with transplantation, immunosuppression to prevent organ rejection, together 
with the general complexity of the procedure and long recovery period. Furthermore increasing demand 
for donor organs means that patients with comorbidities generally do not receive donor organs, due to 
poor chances of success (reviewed in (Mangini, et al., 2015)). 
Consequently, there are therapeutic options for a heart affected by TOF, but not for rejected heart. 
(reviewed in (Bernstein & Srivastava, 2012)). Clearly, there is a need for the development of alternative 
therapeutically approach for correction and maintenance of patients with CHDs. 
 
The TOF pathology is associated with intra-cardiac shunt within intra-ventricular septal wall and 
obstruction of blood flow passing from RV to pulmonary arteries (Avolio, et al., 2015(c)) (see Figure 2). 
The VSD allows the mixture of oxygenated and deoxygenated blood, interfering with normal circulation; 
while stenosis of the PA increases hydrostatic pressure and shear stress experienced by vessel. Overall 
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this results in hyperplasia of RV wall due to high work load, necessary to pump blood through the small-
diameter pulmonary artery. Therefore in order to optimize heart function, both the obstruction and 
shunt must be eliminated. Currently approved therapy requires surgical intervention involving the 
closure of VSD, the opening of pulmonary outflow track, and in more severe cases replacement of the 
pulmonary semilunar valve. After PA augmentation and closure of VSD, the symptoms such as cyanosis 
eliminate (reviewed in (Sun, et al., 2015)). 
 
Figure 2: Anatomical structure of healthy heart and heart with TOF pathology. The direction of the 
blood flow is indicated with arrows. 
A: Blood flow in the healthy human heart  
B: Schematic representation of the TOF pathology with altered blood flow. Red boxes indicate structural 
abnormalities observed in TOF and result in the inability of the heart to perform its normal function.  
Arrows indicate the direction of blood flow, and their color corresponds to the saturation of blood with 
oxygen (red-oxygenated blood; blue- de-oxygenated blood; purple-mixed blood.  
Tetralogy of Fallot (TOF) 
The heart prostheses including conduits, patches, and valves. These grafts originate either from 
biological materials or are synthetic. While synthetic materials are relatively easy in production, they are 
unable to support tissue growth. Furthermore, they are not recommended as a small conduit due to the 
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risk of thrombosis and inflammation associated with them (Allen, et al., 2002) (reviewed in (Klouda, et 
al., 2014) (Chaikof & Elliot, 2010)). Biological grafts on the other hand, possess ideal characteristics in 
terms of integration, and growth however, the supply of donor organs is limited (reviewed in (Jakus, et 
al., 2008)). Xenografts originate from animal tissues, which undergoes residential cell depletion before 
transplantation. These animal-derived grafts are highly available, but they can only present a temporary 
solution. Following the transplantation of xenograft the remaining cellular debris undergoes 
calcification, which increases the risk of thrombosis, atherosclerosis, and inflammation (Harmoodi, et al., 
2015).  
 
Generally, the issues associated with cardiac muscle repair is often addressed by the complexity of the 
organism. The lower order animals, such as zebrafish, have a high capacity of heart regeneration 
following cardiac tissue damage, while human ancestors have lost this ability throughout evolution ( 
Poss, et al., 2002).  
Cardiac development, as well as most of the cardiac growth, occur during embryogenesis. Heart muscles 
are post-mitotic tissues and have very poor capacity for self-regeneration. It was originally considered 
that adult cardiomyocytes lack the ability to re-enter cell cycle, even in response to damage.  
The current view, however, supports the idea that subsets of cells residential inside the heart are capable 
of endogenous reparative processes (reviewed in (Shiojima & Walsh, 2006) (Beltrami, et al., 2001). The 
extent of repair occurring within a fully grown heart following the loss of cardiomyocytes in response to 
hypoxic damage is limited to the generation of scar tissue (Michiels, 2004), which is unable to support 
еthe electrical activity of the heart. Cardiomyocytes of neonatal heart possess modest proliferation 
capacity and may potentially re-enter cell cycle in response to damage to prevent further cell loss ( 
Senyo, et al., 2013) (Porrello, et al., 2011). In a fully grown adult heart healing occurs through the 
replacement fibrosis and local cardiomyocyte hypertrophy. In young individuals heart is capable of 
undergoing regeneration though to a very limited extent. (Beltrami, et al., 2001).  
Contractile properties of the myocardium diminish as a result of the replacement of the damaged tissues 
by fibrosis. Over time this elevates the mechanical stress experience by the surrounding tissues, which 
eventually results in decreased pumping capacity of the whole organ (Klabunde, 2012) (reviewed in 
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(Blum & Benvenisty, 2008). Eventually, the condition progresses to HF as the heart is unable to establish 
sufficient pressure to distribute blood throughout the body (reviewed in (Blum & Benvenisty, 2008).  
 
Despite previous belief cardiomyocytes are not preserved throughout the life. Studies had shown that 
heart has the limited regenerative capacity and cardiac muscle cells are generated long after foetal 
development (Bergmann, et al., 2009). Within heart tissues, small subpopulations of stem and 
progenitor cells occur in specialised areas called niches and act as a ‘cardiac cell reserve’ (Torella, et al., 
2006). These cells are essential for tissue homeostasis as they are capable of myocyte and vascular cell 
replenishment through self-renewal and differentiation and thus counteract myocyte attrition (Nadal-
Ginard, et al., 2003 a) (Nadal-Ginard, et al., 2003 b).  
The human CSCs (hCSCs) occur in the niches in a quiescent state and upon external stimuli can undergo 
activation and asymmetric cell division to generate a pool of daughter cells of myogenic fate. These 
progenitor cells eventually differentiating to produce novel cardiomyocytes and vascular residential cells 
including VSMCs and ECs (Urbanek , et al., 2006). However, the phenotype of hCSCs is strongly affected 
by biological rather than chronological age. For example, the deterioration of cardiac function has been 
partially attributed to the accumulation of senescence cells (reviewed in (Rota, et al., 2015).  
Senescent cells is essentially a cell that is irreversibly restricted in G₀ phase of cell cycle and so is unable 
to re-enter cell cycle. There is no single marker for cellular senescence but the increase in p16INK4a and 
p53BP1, both of which restrict cell in G₀ phase (Gonzalez, et al., 2008). The increase in the expression of 
some markers including SA-beta-galactosidase, gH2AX, CDKN2B and CD295 leptin receptor, together 
with decline in PTN, MCM3, Stro-1, CD106 and CD146 are also used to assess cellular senescence 
(reviewed in (Rodier & Campisi, 2011)) (reviewed in (Hooten & Evans, 2017)) (Jin Jin, et al., 2016). The 
ageing is the single most common cause of cellular senescence is shortening of chromosomal ends the 
telomeres, which decrease by ~130bp per division, eventually resulting in genomic instability and 
impaired proliferation of progenitor cells (Bearzi, et al., 2007). These cells give rise to the population of 
daughter cells unable to re-enter the cell cycle leading to declining in the number of functionally 
competent cells that would normally contribute to homeostasis and regeneration. 
Another factor contributing to CSC senescence, including reduced cellular apoptosis leading to 
accumulation of functionally impaired progenitor cells within niches(reviewed in (Rota, et al., 2015). The 
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underlying pathologies can also cause functional alterations within the heart and increase the cellular 
senescence. For example changes in the cellular environment and stress can cause the accumulation of 
senescent cells even at an earlier age due to telomerase-independent cellular ageing (reviewed in 
(Lapidot & Petit, 2002)). 
The net loss of myocytes hence impairs organ function and promotes the ageing (Torella, et al., 2006). 
Depletion of functionally competent progenitor cells can also affect the phenotype of mature 
cardiomyocytes and result in impaired intracellular Ca²⁺ regulation, which disrupts the normal heart 
cycle and promotes arrhythmia (Lakatta & Levy, 2003).  
Interestingly the number of hCSCs was shown to elevate following acute LV infarct. As the condition 
progresses to the post-infarction cardiomyopathy the number of hCSC within chronic infarct declines, 
however it still remains above the base level of controls (Urbanek, et al., 2005). Instead of compensating 
for the cardiomyocyte and vascular tissue loss, these cells undergo a phenotype transition to become a 
senescent cells, which can no longer regulate tissue homeostasis and lead to further cell loss and organ 
damage (reviewed in (Torella, et al., 2006)). 
The build-up of senescent cells also affects signalling within the niche itself, for example, the decrease 
in signals regulating cell proliferation such as IGF-1 and HGF interfere with the function of remaining 
progenitor cells . However, such changes were shown to at least partially reversible in rat animal model. 
The rat CSCs managed to successfully migrate to the site of damage and generate new cardiomyocytes 
following activation with growth factors (GFs) (Gonzalez, et al., 2008). Such finding indicates that 
potentially similar approach could be used in the future to partially reverse senescence-associated 
pathophysiological conditions of ageing heart (Avolio, et al., 2014).  
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 Mural cells 
The heart is largely comprised of connective, epithelial, and nerve tissues (reviewed in (Pinto, et al., 
2016). Numerically, epithelial cells are the most abundant and outnumber cardiomyocytes by as much 
as 3:1 (Hsieh, et al., 2006). However, cardiomyocytes take up as much as 75-86% of the total volume 
(Zhou & Pu, 2016). The cardiomyocytes are surrounded by a network of capillaries, which provide 
metabolic supply and enable gaseous exchange and localised endocrine signalling. This cardiac 
vasculature is arranged so that cardiac muscle cells are located close to at least one microvascular 
branch. 
The coronary microvessels are mainly composed of two cell types, ECs, and pericytes. Pericytes cells are 
vascular support cells, also known as mural cells, which surround the endothelial cells that form the 
lining of the blood vessels. Pericytes appear early in foetal development and have been shown to play a 
role in vascular development, homeostasis and haemostasis (Hsieh, et al., 2006). 
 
Pericytes are located in the peri-endothelial compartment in the microvasculature. These are embedded 
in the basement membrane alongside ECs. Furthermore, these cell types mediate direct communication 
through peg-socket junctions (reviewed in (Attwell, et al., 2016)).  
Meanwhile, the definition of pericyte remains a matter of debate, as these cells exhibit a wide 
heterogeneity within and between different organs. Studies of pericytes isolated from different 
anatomical locations including kidney (Stefanska, et al., 2016), brain (Rustenhoven, et al., 2015), eyes 
(Do, et al., 2017) and heart (Avolio, et al., 2015 (a)), show antigenic and functional variation. 
Consequently, dysfunction of pericytes at the different anatomical location may also contribute towards 
pathology to a variable extent.  
During the embryonic development, the plexus vessel is initially formed by splitting from the aorta. The 
research looking into the development of vessel plexus of mouse embryos had provided some insights 
into the origin of pericytes located in the heart. The plexus vessel is initially formed during embryonic 
development by split from the aorta. Firstly the cells surrounding plexus vessels appear to possess 
characteristics of the pericytes. They share basement membrane with ECs, appear rich in collagen type 
4, express platelet-derived growth factor receptor-beta (PDGFR-β), neural/glial antigen 2 (NG2) and 
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Notch3, while appearing to be negative for the smooth muscle myosin heavy chain (SM-MHC) and α-
smooth muscle-actin (α-SMA) (Volz, et al., 2015) (Kumar, et al., 2017).  
During embryonic day 13.5, the vessel plexus reattaches to feeding aorta. The cells of pericyte-like 
nature, the surrounding vessel then start transdifferentiating to SMC-like phenotype. They acquiring 
expression of the SM-MHC, which is the recognizable feature of the mature vessel (reviewed in (Attwell, 
et al., 2016)). The expression of SM-MHC marker by those cells is higher around the area of attachment 
to the aorta, while the regions further away are initially negative and require a longer period of time to 
induce marker expression (Chen, et al., 2014). After the mural cells of vessel plexus acquire SM-MHC 
expression throughout the tissue, further maturation occurs, which is characterised by the expression of 
contractile smooth muscle markers including α-SMA and α-calponin 1 (reviewed by (Rensen, et al., 
2007)), eventually resulting in the formation of mature coronary vessels. The entire process of coronary 
vessel maturation is believed to be regulated by Notch3 pathway initiated by receptor-ligand pair formed 
between EC and SMC of the aorta and triggered by vessel plexus perfusion (Volz, et al., 2015).  
 
While the origin of pericytes is still not fully understood, their contribution to the vessel formation, 
stability, and maintenance are recognized (reviewed in (Belgers & Song, 2005)). Apart from tissue 
homeostasis upon external stimuli pericytes are also associated with angiogenesis and tissue 
remodelling (Invernici, et al., 2007) (Chen, et al., 2015).  
Perivascular cells possess features of both stem and progenitor cells, and so may contribute to tissue 
regeneration. They appear to share many characteristics with MSCs such as capacity to transdifferentiate 
towards multiple lineages including adipocytes, osteoblasts, and VSMC (Volz, et al., 2015) Pericytes 
represent a very heterogeneous population of cells with variable protein expression, function and so 
their contribution to regeneration/repair and/or pathology may be defined by the organ of origin as well 
as any underlying pathologies (reviewed in (Attwell, et al., 2016)). 
In vivo spatial arrangement of pericytes in relation to ECs (see Figure 3) allows controlled interplay 
between their receptors and ligands and thus regulates vessel homeostasis (Geevarghese & Herman, 
2014). Some speculate pericytes are the primary source of essential nutrients for ECs. This idea is 
supported by in vitro experiments, which showed that in the absence of pericytes, ECs require more 
complex culture media for proliferation (reviewed by (Nees , et al., 2012)). In the animal model, the  
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Figure 3: Diagram of external structures and cross sections of the Large vessel and small capillary. Cross section of the large vessel represents 
the three layers of tissue: tunica adventitia, tunica media, and tunica intima. Tunica intima composed of ECs line the internal cavity working 
as a barrier and separating organ from blood flow. Tunica media, separated from tunica intima by BM and elastic lamina and is composed of 
SMCs, responsible for vascular tone. External elastic membrane, which separates tunica media from tunica adventitia, is the outermost layer 
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of vessel composed mainly of collagen and provide support and integrity to the organ. Apart from collagen tunica adventitia contain vasa 
vasorium and vasculogenic niches. The vasa vasorum works as a tiny vessel and provides blood supply to the vascular tissue. The vasculogenic 
niches are areas that containing vascular progenitor cells including APCs essential for vessel growth and maintenance. The capillary shown as 
diversion of the vessel has a less complex structure and is composed of a layer of ECs lining up the internal region, surrounded by pericytes 
sharing basement membrane with ECs.  




Figure 4: Mature and progenitor vascular cells 
composing vessels.  
Acronyms of Figure 3 
Adventitia progenitor cells (APCs), endothelial 
cells (ECs),endothelial progenitor cells (EPCs), 
mesenchymal stem cells (MSCs), smooth muscle 
cells (SMCs),  
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the absence of PCs correlate with endothelial hyperplasia and enhanced transendothelial 
permeability and is associated with the development of dilated cardiomyopathy after mouse 
embryonic day 13.5 (Hellström, et al., 2001).  
Both the poor EC-pericyte communication and reduction in pericyte number is associated with 
vascular dysfunction. The density of pericytes within the microvasculature is specific to each 
organ. For instance, within vessels of LV of the heart, the density of pericytes was reported to 
reach ~3.6x10^7cells/cm³, suggesting pericytes to be the second most abundant cell type 
(reviewed by (Nees , et al., 2012) (Pinto, et al., 2016)). So unlike LV, where the ration of pericytes 
to ECs is anywhere between 2:1 and 3:1, the skeletal muscles only have one pericyte per hundred 
ECs (reviewed in (Armulik, et al., 2005)). 
 
The identification of pericytes is based on multiple criteria including their morphology, protein 
expression and location. Functional properties, such as the formation of tubular structures when 
co-cultured with ECs on the matrigel are additional criteria that can aid in pericytes identification 
(reviewed in (Avolio Elisa, 2016)).  
While it is challenging to distinguish pericytes from other cell types, there is also a huge variation 
between pericytes isolated from various niches. Different research groups reported 
phenotypically distinct pericytes isolated from the same organ, hence the pericytes obtained in 
different laboratories from the same organ can represent different sub-populations with diverse 
characteristics and variable potential for the regeneration and repair (reviewed by (Attwell, et 
al., 2016)). Within vascular bed of a single organ, antigenically distinct pericytes had been isolate 
before. In terms of human heart, two subpopulations have been reported. The CD146+/CD34- 
human cardiac residential perivascular cells isolated from human bodies post-mortem (Chen, et 
al., 2015) and CD34+CD105+/CD146-isolated from heart tissue leftovers obtained from patients 
undergoing heart palliative surgeries (see Table 1) (Avolio, et al., 2015 (a)). 
Unfortunately, the statement made by Zimmermann in 1923 that the main issue associated with 
the study of pericytes is the lack of unique specific markers, is still valid (Nees , et al., 2012). Due 
to their heterogeneous nature and variation in morphology, protein expression and function, 
there is still a lack of agreed definition of what pericytes is, hence the confusion and arguments 
still occur in the literature (reviewed in (Attwell, et al., 2016)).  
Chapter 1: Introduction 
16 
Despite troubles caused by the absence of unique markers expressed by pericytes, it is still 
possible to distinguish them from ECs and VSMCs. In terms of morphology, pericytes have 
multiple elongated processes, which allows them to be easily distinguished form ECs when 
observed under the microscope (reviewed in (Nees , et al., 2012)). Pericytes also share many 
similarities with SMCs, but they also have many distinctions including the contractile protein 
expression; for example, pericytes in vitro express synthetic SMC markers, while lacking 
expression of early non-specific contractile markers (reviewed by (Wanjare, et al., 2013)).  
Still, it is often difficult to distinguish pericytes from SMCs, fibroblasts, MSCs or macrophages due 
to the similarity in morphology and overlapping markers. As a consequence different research 
groups may classify what appears to be the same cell types differently. Previously, the two 
studies investigated the effect of cellular contraction and relaxation on the blood flow within 
microvasculature. Despite two research groups identified what is believed to be the same subset 
of cells, regulating microvasculature tone, the lack of agreement in cell classification aroused. In 
the paper by Hall et at effector cells were defined as pericytes (Hall, et al., 2014), while the study 
by Hill et al named those SMCs (Hill, et al., 2015). This is a great example of issues associated with 
the lack of agreed definition for perivascular mural cells, complicated by morphologic, functional 
and antigenic similarities to VSMCs (reviewed by (Attwell, et al., 2016)). 
The greatest misperception still occurs between the pericytes and VSMCs, which belong to the 
same mesenchymal lineage. Markers used to distinguish mural cells appear to be nonspecific 
while their expression can vary depending on changes in the environment (Chen, et al., 2015) 
(Avolio, et al., 2015 (a)).  
 
Another phenotypically similar population of cells exist, known as adventitial progenitor cells 
(APCs). These cells occur in larger vessels, however, they are similar to pericytes in terms of 
localization, function and, morphology.  
The APCs were distinguished from pericytes based on both perivascular location (see Figure 3) 
and markers expressed by these cells (reviewed in (Crisan, et al., 2012)). The CD34+ vascular 
progenitor cells were first identified in the adventitia of human foetal aorta. Based on flow 
cytometry the cells appeared to be positive for CD133, CD34, kinase insert domain 
receptor/vascular endothelial growth factor receptor 2 (KDR/VEGFR2), and Tie-2 and negative  
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Figure 5: Structure and morphology of the Synthetic and Contractile phenotype of VSMCs. The Phenotype spectrum of the VSMCs is defined 
by epigenetic programming and hence the cell characteristics vary depending on the external stimuli. The distribution of organelles within cell 
correlates with morphology and defined by function. Synthetic VSMCs appear rhomboid with wide endoplasmic reticulum and large Golgi 
apparatus; while contractile VSMCs, the elongated morphology with arranged contractile filaments and both small endoplasmic reticulum and 
Golgi apparatus.  
Furthermore, it is hypothesized that these cells are capable of undergoing phenotypic modulation and hence two phenotypes present intricate 
classification. 
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Table 1: Pericytes previously characterized and explored for their potential application in heart 
regeneration as a stem cell-based therapy. The major markers, identified for each cell type is presented 
together with the origin of the cell and the effect the cells exert upon introduction to the area of damage 
in disease animal model 
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for CD31, Von Willebrand factor (vWF) and CD146-. They also possess multiple characteristics of 
progenitor/stem cells including co-expression of endothelial and myogenic markers together with high 
potency for angiogenesis and myogenesis. Furthermore, upon exposure to differentiation media in vitro, 
the cells acquired endothelial-like and mural-like phenotypes (Invernici, et al., 2007). Later, a similar 
population of cells, the CD34+ SVPs were also isolated form adventitia of saphenous vein leftovers 
following coronary artery bypass surgery in adult patients (see Table 1) (Campagnolo, et al., 2010). 
Meanwhile, the CD146 was recognized as a marker of perivascular cells residential within the 
microvascular region. Perivascular cells, which appeared negative for CD146, while expressing CD34 
were hence defined as APCs, such as SVPs (see Table 1) (Campagnolo, et al., 2010).  
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However more recent paper identified a similar population of cells within cardiac tissue, which appeared 
CD34+/CD146- (see Table 1). These cells were hence termed cardiac pericytes (CPs). The heart tissues 
were collected from neonatal patients undergoing TOF palliative surgery. Surprisingly, based on 
histological stainings those cells were located both within capillaries and vasa vasorum of larger vessel 
adventitia (Avolio, et al., 2015 (a)). Further analyses of CPs showed higher expression of NG2 and stem 
cell antigens as well as higher level of GF secretion when compared to SVPs (Avolio, et al., 2015 (a)). 
 
Systemic blood pressure is the force generated by blood moving through the vessels. On a large body 
scale, the blood pressure is defined by the total volume of blood pushed during ventricular contraction 
and vascular resistance and may be influenced by the arterial resistance. 
Local intravascular blood pressure is regulated by the contraction and relaxation of VSMCs situated 
within tunica media, by changing the diameter of the vascular lumen, which in turn affect the internal 
pressure (reviewed in (Rensen, et al., 2007). VSMCs and cardiomyocytes both belong to SMC lineage 
(reviewed in (Wang, et al., 2015)), to the mechanism underlying the nature of their contraction varies 
greatly. There are still some similar to cardiomyocytes and VSMC contract in response to membrane 
depolarization, which triggers the opening of voltage-gated L-type calcium channels, allowing an influx 
of Ca#$. This triggers calcium induced calcium release via ryanodine receptor/inositol trisphosphate 
(RyR/IP3) coupling from the sarcoplasmic reticulum (reviewed in (Brozovich, et al., 2016) (Feridooni, et 
al., 2015)). Following elevation of cytosolic Ca#$, its ions bind to calmodulin which triggers activation of 
myosin light chain kinase (MLCK). The MLCK then phosphorylates myosin light chain (MLC) a regulatory 
subunit located within the head of myosin heave chain. Eventually, this results in cross bridging of actin 
and myosin filaments, causing cells to contract (reviewed in (Amberg & Navedo, 2013)). VSMC 
contraction regulates vascular tone which elevates local blood pressure whilst cardiomyocyte 
contraction causes chambers to contraction which pushing blood away from heart. For VSMCs Ca#$ also 
act as a transcription factor (TF) of VSMC markers, altering the gene expression and cellular response 
(reviewed in (Brozovich, et al., 2016)). However, unlike cardiomyocytes, VSMCs always require an 
extrinsic signal to generate contraction, and do not possess intrinsic myogenic activity. 
The VSMCs regulating vascular tone, as described above, belong to contractile phenotype. However, 
there is another VSMCs phenotype, the synthetic, which have different antigenic and functional 
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characterisation when compared to contractile subpopulation(see Figure 5) (reviewed in (Rensen, et al., 
2007)).  
The SMCs located within tunica media are classified as contractile VSMCs and regulate the degree of 
constriction experienced by blood vessel. However VSMCs present phenotypic plasticity (see Figure 5). 
For example upon isolation and sub-culturing in vitro these cells undergo de-differentiation to become 
more proliferative phenotypic. These cells are defined as synthetic SMCs as they lose expression of 
contractile VSMC markers, especially SM-MHC, which is major contractile protein capable of converting 
chemical energy into physical through ATP hydrolyses (Rensen, et al., 2007).  
Within adult vasculature, the contractile VSMCs phenotype is predominant and increase in a number of 
synthetic cells is normally associated with pathologic events for example following infection or 
mechanical damage of tissue, the inflammation triggers VSMC to undergo a transition to synthetic 
phenotype (reviewed in (Heusch, et al., 2014)). 
 
From previous studies conducted on SVPs (Campagnolo, et al., 2010), human myocardial pericytes (Chen, 
et al., 2013) and CPs (Avolio, et al., 2015 (a)) it appears these cells can be easily isolated and produce a 
high number of cells upon sub-culturing (see Table 1). Pre-clinical trial had investigated the therapeutic 
effect of combinatory therapy with SVPs and CSCs in the mouse model of infarcted heart (Avolio, et al., 
2015 (b)) and peripheral limb ischemia (Gubernator, et al., 2015) showed a decrease in infarct size and 
enhanced angiogenesis. The underlying mechanism of the tissue regeneration is still not fully understood 
but is believed to be attributed to miRNA-132 secretion by transplanted SVPs (Katare, et al., 2011). In 
another study, it was observed that a decrease in cardiac infarct size following transplantation of human 
myocardial pericytes alone and was attributed to IL6 and other anti-inflammatory cytokines secreted by 
those cells (Chen, et al., 2015).  
Neonatal CD34+/CD146- CPs were previously extensively characterised and based on results appeared 
to participate directly and indirectly in angiogenesis. Additionally, they were capable to recruit ECs and 
cKit+ cardiac progenitor cells through secretion of paracrine factors in vitro. Furthermore, neonatal CPs 
were shown to transdifferentiate to vascular smooth muscle cells (VSMCs) upon exposure to 
differentiation media, suggesting their high plasticity and differentiation potential (Avolio, et al., 2015 
(a)). The study by Gubernator et al on SVPs also had shown that the therapeutic effect possessed by cells 
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was invasively proportional to the age of pericyte donor, raising the question whether pericytes incur in 
senescence during ageing (Gubernator, et al., 2015). Hence even though CPs have only yet been studied 
in vitro, in order to determine if they conserve their healing potential CPs of adults need to be further 
characterised. 
  
Chapter 1: Introduction 
22 
 
 General context of the present research 
My work is part of a project funded by the British Heart Foundation investigating the potential use of 
autologous human CPs for application in tissue engineering for correction of CHD. For this purpose, CPs 
were obtained from young patients aged 1 to 17 months and characterised for their ability to repopulate 
decellularized xenografts. We also collected CPs from adult CHD patients undergoing secondary cardiac 
surgery. This offered us a unique opportunity to compare CPs in relation to the age of the donor and 
verify if the ageing process can affect the cell phenotype and functionality. While the pro-angiogenic 
capacity of paediatric CPs was investigated and described in (Avolio, et al., 2015 (a)), so far the adult CPs 
(aCPs) were never obtained and characterised before.  
Hypotheses 
The neonatal heart has a remarked regeneration potential due to its young age. A high number of stem 
cells is still retained in the organ shortly after birth, and hence we hypothesize newborn CPs (nCPs) to 
be involved in the process of heart regeneration.  
On the contrary, the adult’s heart self-regeneration capacity is known to be very limited and is generally 
restricted to tissue repair (Michiels, 2004). Furthermore, the ability of young CPs to transdifferentiate 
into VSMC was previously reported (Avolio, et al., 2015 (a)). We further hypothesize that through the 
transdifferentiation to VSMC phenotype, CPs could directly contribute to novel arteries formation in 
the newborn heart, conferring the organ with a great healing capacity after an extensive injury such a 
severe myocardial infarction (Haubner, et al., 2016).  
We finally hypothesize that through adolescence to the adult life this plasticity of CPs is lost together 
with other functional properties, diminishing their important angiogenic and pro-healing capacity.  
 
Based on the hypothesis defined above, the aim of the study is to isolate and characterise CPs from 
newborn and adults hearts from patients with congenital heart disease, and to compare results of 
nCPs and aCPs to see if the process of aging affects functional properties of cells. 
To this purpose, adult cells (isolated from patients aged 14 to 54 years) were compared to the paediatric 
nCPs (isolated from patients under 30 days of age), with regard to the typical antigenic profile, protein 
expression, secretome content, differentiation capacity and proangiogenic properties. 




In order to antigenically characterise nCPs and aCPs, an extensive marker panel was used as no single 
marker has been identified for pericytes. Through immunocytochemical (ICC) approach expression of 
pericyte (including NG2, PDGFR-β, Vimentin), stemness/proliferation (OCT4, SOX2, NANOG), contractile 
and synthetic VSMC, endothelial, and connective tissue markers were performed. The results showed to 
what extent the nCPs and aCPs are antigenically comparable. 
 
Conditioned media (CM) from nCPs and aCPs were then examined using enzyme-linked immunosorbent 
assay (ELISA) to assess the level of pro-angiogenic GF secretion. The pro-angiogenic potential of the CP-
derived CM was then further investigated as the ability to enhance tube formation by coronary artery 
endothelial cells (CAECs) on matrigel. 
 
Two major functional assays were used to assess angiogenic potential and cellular plasticity of nCPs and 
aCPs. First the ability of nCPs and aCPs to directly contribute to network formation by CAECs on matrigel, 
and then the potential of these cells to differentiation into VSM-like cells.  
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 Primary cell lines generation 
All patients recruited in this study had undergone cardiac surgery for correction of CHD (REC reference 
15/LO/1064). Myocardial tissue leftovers from either atrium or ventricle were collected by Prof Massimo 
Caputo, a congenital heart surgeon at the Bristol Royal Hospital for Children and Bristol Royal Infirmary 
– Bristol Heart Institute. All samples were obtained through patients fully informed consent. Adult 
patients (16 years and above) consented for themselves, while parent/legal guardians consented for 
newborn and children (<16 years). Patients aged 11-15 years were given the opportunity to assent. 
Following consultation with the cardiac surgeon, for our study, we considered patients aged 14 and 15 
years as adults. This decision was dictated by the fact that the heart at this age would have reached the 
final development of an adult heart.   
Table 2: List of CP cell lines used in the current study. All cell lines were extracted from human tissues 
using the SOP described in section 2.2.1. Right atrium (RA), right ventricle (RV), total anomalous 
pulmonary venous connection (TAPVC), transposition of the great arteries (TGA), ventricular septal defect 
(VSD), atrial septal defect (ASD), tricuspid valve replacement (TVR), pulmonary vascular resistance (PVR). 








CP2 RA TAPVC 16 days 
CP16 RA TGA 16 days 
CP21 RV Pulmonary atresia 11 days 
adult 
(>12 years) 
CP22 RV N/A 14 years 
CP24 RA ASD 54 years 
CP25 RV TVR+PVR 23 years 
 
The cells were isolated from six samples of cardiac tissue leftovers (see Table 2). The SOP applied for the 
CPs’ extraction was originally designed for the SVPs’ extraction (Campagnolo, et al., 2010) and later 
adjusted for CPs (Avolio, et al., 2015 (a)). 




Prior processing cardiac tissues obtained from surgeries were stored in Dulbecco Modified Eagle Medium 
(DMEM) (Gibco by Life Technology REF#31885-023 Lot#1791397) at 4˚C. During the isolation procedure, 
the samples (see Figure 6) were washed vigorously with Dulbecco Phosphate Buffer Saline  
 
Figure 6: Human cardiac tissue samples obtained during corrective heart surgery. These tissues 
undergo processing for CP extraction. Samples shown in this picture were not involved in this study, and 
are shown for illustration purpose only. 
(DPBS) (Gibco Life Technology LOT#1870721 REF#14190-094) and then manually minced until nearly 
homogeneous (see Figure 7 A-C). 
 
Figure 7: Sample preparation for enzymatic digestion. 
A: Unprocessed piece of human cardiac tissue.  
B: Small amount of medium added to wet the sample. 
C: Sample manually minced with scissors and blade to generate homogenous mass. 




The cells were spun for additional 10 minutes at 400rcf (relative centrifugal force) following re-
suspended of the pellet. The homogenised tissue mass was then washed in DPBS and centrifuged for 10 
minutes at 400rcf. Pellet was then resuspended and digested with 0.45WU/ml of Liberase 2 enzyme 
(LIBDH-RO Roche) in DMEM for 30 to 60 minutes at 37˚C. The time of digestion was adjusted depending 
on the weight of the tissue. After the enzymatic digestion (see Figure 8 A), the suspension was passed 
through 70%& and 40%& strainers and then centrifuged for 10 minutes at 400rcf. The pellet was then 
re-suspended in DMEM and passed through a 30%& strainer, which ensures single cell suspension to be 
formed (see Figure 8 B). 
The cells were re-suspended in column buffer (PBS supplemented with 0.5% bovine serum albumin (BSA) 
(BSA LOT# PH 206816 Prod# 23209 Stock concentration=2mg/ml) and 2mM of 
ethylenediaminetetraacetic acid (EDTA) (EDTA Ambion The RNA Company P/N:AM9260G LN:1509002)). 
 
Figure 8: Enzymatic digestion of cardiac tissue and the generation of single cell suspension.  
A: Processed human cardiac tissue digested with Liberase 2 enzyme.  
B: Falcon filters of 70, 40 and 30 %& used to successively pass digested cardiac tissue, to yield single cell 
suspension. 
The blocking solution (provided together with beads) was then combined with CD31 beads (Miltenyi 
Biotics 130-091-935) and were added. The suspension was vortexed and incubated for 30 minutes at 
4˚C. After that, the cells were vortexed quickly and centrifuged for an additional 10 minutes at 400rcf.  





Figure 9: Diagram of immunomagnetic cardiac pericyte extraction. Summary displaying essential steps 
of CP extraction and isolation from the human surgical sample. The selection was based on the size of 
the cells (<30µm) and antigenic phenotype (CD31-negative/CD34-positive). The expected purity or 
resulting population was between 70-85% as suggested by Miltenyi Biotics. Consequently there was 
present a significant level of contamination with cells of unknown phenotype within initial cell 
populations before those were further expanded. Hence the final decision regarding the nature of the 
cells isolated and the purity of the cell lines generated was made after they got expanded and 
characterised. Such caution was further dictated by the absence of universal pericyte marker and 
overlapping antigenic profile of pericyte with other hematopoietic, mesenchymal and mural cells.  
It is however, important to add, that due to the issues with absence of universal pericyte molecular 
marker, only after expansion and assessment of other cellular characteristics (morphology, extended 
antigenic phenotype and functional assay) of newly produced primary cell line, the assumption regarding 
the purity and quality of the cell line could be made. 




The cell pellet was then re-suspended in cold column buffer and suspension passed through MS-column 
(Miltenyi Biotics 130-042-210) placed on the MACS Multi-stand magnet (Octo'()*+' Separator 130-
042-109 and MS Column Holder Multistand 130-042-303). First, the ECs were depleted using anti-CD31 
conjugated beads with magnetic column and the flow through was collected. This step eliminated CD31 
expressing cells, which remained in the column. The process was then repeated with the flow incubated 
with anti-CD34 conjugated beads (Miltenyi Biotics 130-042-201). This time, the flow through was 
discarded, while the cells attached to MS-column (CD31-/CD34+ phenotype) were isolated by removing 
MS-column from the magnet and washing with adding 1ml of column buffer. The resulted cells of 
interest were span again and re-suspended in fresh Endothelial Cell Growth Media-2 (EGM-2) (Lonza CC-
4176). The full method of tissue processing and isolation (see Figure 9). The resulting CPs at P0, were 
cultured and expanded using the complete EGM-2 media supplied with 2% Foetal Bovine Serum 
(provided as part of complete growth kit for EGM-2 media) at 37˚C.  
 
Newly isolated CD31-/CD34+ cells were defined as CPs, however during this project the formal 
phenotyping was only done after reaching passage 5/6. Hence the actual purity of the cell line and the 
level of contamination was not assessed during this project due to shortage of cell lines available.  
Once isolated cells had reached confluence in the flask, they were split and seeded onto the new dish to 
avoid cell detachment and death. The confluent cell lines were washed twice with DPBS and depending 
on the density of the monolayer formed trypsinized (Trypsin-EDTA, Life Technology) for the maximum 
of 5 minutes at 37°C. Following deactivation of the enzyme with the blocking solution (10% foetal bovine 
serum (FBS) in DPBS), the suspension would then be collected and centrifuged (Eppendorf 5702 Series 
Centrifuge) for 10 minutes at 400rcf. The pellet was then re-suspended in fresh complete EGM-2 with 
2% of FBS. In order to determine the cellular number small amount (5-10%,) of cellular suspension was 
stained with the trypan blue (0.4%, Gibco by Life Technology REF# 15250-061) and calculated under the 
microscope using Burker counting chamber. After that, the cells would be seeded in the new T25 flask 
(Greiner Bio-one Cat# 690-1600) at the density of 8,000 cells per square centimetre (cm²) and cultured 
in complete EGM-2 media at 37°C.  
  




 Additional cell lines used in this study 
Most of the work was performed using nCPs and aCPs. However other commercially available cardiac 
cells were employed in this study. The coronary artery endothelial cells (CAECs) were used for matrigel 
angiogenic assay to analyse the potential of CPs to influence cellular tube formation directly and through 
the action of paracrine factors. Also, the other commercially available cardiac residential cells were used 
as controls for ICC-IF (see appendix 1). 
Human coronary artery endothelial cells  
Human CAECs are commercially available cells sold by PromoCell (PromoCell C-12221). These cells were 
cultured and expanded following the manufactures recommendations. Based on supplier 
recommendations, the Endothelial Cell Growth Media (ECGM PromoCell C-22022) was used for cell 
culturing at 37°C 5%CO₂. The human CAECs were used for matrigel angiogenic assay to determine the 
potential contribution of nCPs and aCPs to CAEC cellular tube formation (see subsection 2.5.1).  
  




 Antigenic characterization 
For the antigenic characterization of cardiac residential pericytes, a panel of antibodies (see Table 3) 
were used for indirect ICC (see Figure 10). The ICC stainings were performed on CPs of newborn and 
adult age groups and their resulting antigenic profiles were analysed and compared.  
 
The comparison in the expression of markers listed (see Table 3) between nCPs and aCPs was performed 
as descried below. Four thousand cells were seeded into each well of corning black 96 multi-well plates 
(Geiner Bio-one REF# 655090 LOT#E17043C) at either P5 or P6, depending on the availability of cell line 
and allowed to reach confluence for around two days (see Figure 11). The cells were then fixed in fresh 
4% paraformaldehyde (PFA) for 15 minutes at room temperature (RT) and washed with DPBS. Staining 
for each marker tested was performed in duplicates. For antibodies recognizing intracellularly 
compartmented epitope, the cells were permeabilized with 0.1% Triton X100 (Sigma-Aldrich LOT# 
SLBG1525V) in DPBS for 10 minutes at RT prior to blocking. For both connective tissue markers (collagen 
type I and fibronectin) tested, permeabilized and un-permeabilized cells were tested. Five percent FBS 
(quantified, heat inactivated; by Gibco Life Technology REF# 10500-064) in DPBS was used to block cells 
for 30 minutes at RT. Primary antibodies diluted in blocking solution at the rate listed in Table 3 and 
incubated at 4°C Overnight (ON).  
Primary antibodies were then washed off and the cells were then incubated in the dark with the 
secondary antibodies at the dilution 1:200 for 1 hour at RT. After the secondary antibodies, cells’ nuclei 
were stained with Hoechst (1:10,000 dilution) (Sigma Aldrich LOT# ZBE2460V) for 1 minute at RT in the 
dark and then mounted using Fluoromount G (eBioscience LOT# E102581 REF# 00-4958-02) and stores 
at 4°C in the dark.  
The images were produced using a with ZEISS microscope with Axiocam 503 mono Camera (Sony ICX 
674, EXview HAD CCD II ™), which was controlled by ZEN Pro (ZEISS Efficient Navigation) Software.  
The ICC-IF of human cardiac ventricular fibroblasts (CVFs), CAECs and aortic SMCs for the markers listed 
in Table 3 performed followed the protocols described above (see appendix 1). 
  




Table 3:List of markers used for CP characterization.  
The commercially available antibodies for protein detection and visualization were purchased from 
following suppliers (see supplier column). The proteins studied were grouped based on their 
classification:  
1. Canonical pericyte markers: neural glial antigen -2 (NG2), platelet derived growth factor receptor-beta 
(PDGFR-β), Vimentin, CD34, platelet derived growth factor receptor (PDGFR-α), CD146.  
2. Stemness and proliferation markers: sex determining region y-box 2 (SOX-2), octamer-binding 
transcription factor 4 (OCT4), homeobox nanog (NANOG), Ki67  
3. VSMC markers: alpha non-muscle myosin 2B (α-NMMyo2B), alpha-retinol binding protein (α-RBP-1), 
alpha-smooth muscle actin (α-SMA), α-calponin-1, Transgelin, alpha- smooth muscle myosin heavy chain 
2B (α-SM MHC2B), α-Smoothelin.  
4. Endothelial markers; VE-Cadherin, CD31.  
6. Connective tissue markers. Collagen type I, Fibronectin. 
Primary antibodies were stored and used following instruction as stated by the manufacturer. The 
working dilutions listed in this table were initially based on the manufacturer’s recommendations, and 
were later optimized experimentally. The dilutions used were fixed throughout all experiments. Goat 
anti-mouse (anti-Ms) or goat anti-rabbit (anti-Rb) IgG secondary antibodies conjugated to Alexa488 dye 









NG2 yes Millipore (AB-5320) 1:100 Alexa488 Anti-Rb IgG 
PDGFR-β yes Santa Cruz (SC-339) 1:50 Alexa488 Anti-Rb IgG 
Vimentin yes Abcam (ab 92547) 1:400 Alexa488 Anti-Rb IgG 
CD34 no Dako (M7165) 1:20 Alexa488 Anti-Ms IgG 
PDGFR-α yes Santa Cruz (SC-398206) 1:100 Alexa488 Anti-Rb IgG 
CD146 yes Abcam (ab75769) 1:100 Alexa488 Anti-Rb IgG 
2.  
SOX-2 yes Abcam (ab92494) 1:100 Alexa488 Anti-Rb IgG 
OCT4 yes Abcam (ab19857) 1:400 Alexa488 Anti-Rb IgG 
NANOG yes Abcam (ab80892) 1:100 Alexa488 Anti-Rb IgG 
GATA4 yes Abcam (ab61767) 1:100 Alexa488 Anti-Rb IgG 
Ki67 yes Abcam (ab15580) 1:100 Alexa488 Anti-Rb IgG 
3.  
α-SMA yes Dako (M0851) 1:100 Alexa488 Anti-Ms IgG 
α-Smoothelin yes Santa Cruz (SC-28562) 1:100 Alexa488 Anti-Rb IgG 









α-SM MHC2B yes Abcam (ab53219) 1:50 Alexa488 Anti-Rb IgG 
α-NMMyo2B yes Abcam (24761) 1:200 Alexa488 Anti-Rb IgG 
α-RBP-1 yes Abcam (154881) 1:100 Alexa488 Anti-Rb IgG 
α-calponin yes Abcam (46794) 1:100 Alexa488 Anti-Rb IgG 
Transgelin yes Santa Cruz(SC-271719) 1:50 Alexa488 Anti-Ms IgG 
4.  
VE-Cadherin yes Santa Cruz (SC-9989) 1:50 Alexa488 Anti-Ms IgG 
CD31 no R&D system (BBA7) 1:100 Alexa488 Anti-Ms IgG 
5.  
Collagen type I yes/no Chemicon (AB745) 1:100 Alexa488 Anti-Rb IgG 
Fibronectin yes/no Abcam (ab299) 1:200 Alexa488 Anti-Rb IgG 
 
 
CP-derived VSM-like cells of both newborn and adult origin were produced following incubation of CPs 
in differentiation media as described in subsection 2.2. The phenotypes of resulting cell lines were 
analysed using ICC-IF as described in subsection 2.2.1 to study the potential change in the expression of 
pericyte markers, and the acquirement of VSMC marker expression (see Table 3). 
 





Figure 10: the Principle of indirect ICC. The schematic representation of the ICC analysis of the antigenic phenotype of the cells.  
1. Cells were initially seeded in the well;  
2. Cells designated for the detection of the  intracellularly localized epitope were subjected to permeabilization;  
3. Proteins of interest were labelled with primary antibodies and visualised with secondary antibodies conjugated to AlexaFluor488;  




Rabbit/mouse anti-human primary monoclonal/polyclonal antibodies recognized epitopes of the protein that were raised against protein by 
binding to it. The secondary antibodies (goat anti-rabbit/mouse) raised against primary antibodies (rabbit/mouse anti-human) were linked to 
fluorophore molecule, with excitation spectra of 488nm (blue), and emission of 525nm (green). The cellular compartment expressing the 








Figure 11: Schematic representation of 
ICC-IF staining arrangement. The 
expression of the proteins listed in the 
table 3 were assessed for each cell line.  
Orange highlighting correspond to 
intracellularly localized epitopes.  
Blue highlighting corresponds to 
extracellularly localized epitopes. The 
Collagen T1 and Fibronectin are 
synthetized intracellularly and then 
secreted by the cell, so the staining for 
these two was analyzed under both 
permeabilization and unpermeabilized 
conditions 
Reb and green dots represent the nature of antibody raised against human proteins, 
which were either developed in mouse or rabbit respectively. The animal of antibody 
origin determined the secondary antibody used, goat anti-mouse or goat anti-rabbit 
respectively 
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 Molecular characterization 
 
As discussed in the introduction, CPs in vivo are located in close proximity to ECs and 
participate in tissue homeostasis by stabilizing existing vessels. In response to stress pericytes 
also aid in the process of angiogenesis. In order to investigate whether there was an age-
dependent change in the pro-angiogenic potential of CPs, the content of their secretome was 
studied using ELISA (see Figure 12).  
 
Figure 12: Principle of direct sandwich ELISA. The capture antibody (CA) was used to capture 
protein of interest, which was It was then detected using a biotin-conjugated detection 
antibody (DA). By adding streptavidin conjugated to HRP reporter, the streptavidin binds to 
the biotin anchoring HRP to the DA. In the of hydrogen peroxidase, the HRP catalyzed the 
conversion of TMB to charged transfer complex with the development of blue colour. The 
reaction was then stopped by the weak acid, inducing colour change to yellow following the 
diimine molecule formation.  
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Production of CP-derived conditioned media 
CPs were seeded in T25 flasks and were grown in complete EGM-2 media at 37°C under 5% 
CO₂ (Normoxic) conditions. Once cells had reached confluence, they were washed twice with 
DPBS and the complete media was replaced with 3ml of EBM-2 media (Lonza CC3156 
Lot#:00000639689) which does not contain FBS or GFs. These cells were then incubated at 
37°C 5%CO₂ for two days. After 48 hours of incubation, the resulting CMs were collected and 
spun for 5 minutes at 1200rcf to eliminate remaining floating cells. The CMs were then 
aliquoted in Eppendorf’s tubes and immediately transferred to -80°C freezer for long-term 
storage. The number of cells within that T25 flask were then calculated. The CPs were washed 
twice with DPBS and detached using trypsin (as described in subsection 2.1.2).  
The CM was thawed and stored on the ice when needed but returned to-80°C storage when 
not in use. 
Conditioned media analysis with ELISA  
The proteins secreted by CPs of different age groups were quantified using commercially 
available DuoSet ELISA Development System Assay Kits (R&D System). The analyses 
performed are shown in Figure 13. The CP-derived CMs of newborn and adult samples were 
assessed for the presence of human angiopoietin-2 (Ang-2) (R&D System DY623), human 
VEGF (R&D System DY293B) and human angiopoietin-1 (Ang-1) (R&D System DY923). The 
experiments were performed following the general ELISA protocol provided for each ELISA 
kit.  
Briefly the high-binding 96 multi-well plates with flat bottom (Geiner Bio-one REF# 655081 
LOT#E1407151) (see Figure 13) was used for ELISA. All the reagents were provided in the kit 
and were reconstituted, stored, and diluted following manufacturer’s instructions. The plate 
was coated with 100µl of capture antibodies (CAs), and incubated ON at RT. The next morning 
the plate was washed with freshly prepared wash buffer (0.05% of TWEEN 20 (BIO-RAD 
1706531) in DPBS) and incubated with 100μl of either the protein standard provided in the 
kit, or the non-diluted CM (see Figure 13). After 2-hour of incubation at RT, the plates were 
washed three times with wash buffer and incubated for two hours with the detection 
antibody (DA) at RT. Later the DA was washed away, and the plates were incubated with 100μl 
streptavidin-HRP for 20 minutes in the dark at RT. The plate was then washed again and the 
100μl of the substrate solution (1:1 mixture of H₂O₂ and TMB)(R&D System DY994) was added 
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to each well and incubated until the colour had developed for a maximum of 20 minute. The 
reaction was then stopped by adding 50µl of stop solution (R&D System DY994).  
The optical density (OD) was measured using spectrophotometer (DYNEX OpsysMR) at the 
wavelength of 450/570nm. The sample results were standardized using reading obtained 
from protein standard results.  
o   
Figure 13: ELISA assay arrangement in the plate. All ELISA assays were performed using R&D 
System DuoKits following the manufacturers protocol. Each assay included the protein 
standard, sample and blanks.  
Yellow highlight indicate protein standards of known concentrations provided in the kit. 
Green highlight indicate samples obtained from newborn (nCPs) and adult (aCPs). 
Blue highlights: negative controls (EBM-2 and blank). 
 
Western blotting was used to study the expression of PDGFR-α, NG2 and PDGFR-β surface 
receptors. In this particular experiment, three cell lines were used in total, two paediatric (CP5 
and CP21) and one adult (CP24). Particularly, CP5 originated from the atrium of 6 month old 
infant undergoing correction of VSD.  
Cells were pre-seeded in the 6-multi well plates and cultured following procedure described 
in subsection 2.1.2 until they would have reached confluence. They were then kept on ice as 
the media was removed and the CPs were washed twice with cold DPBS. Once DPBS had been 
removed, the radioimmunoprecipitation (RIPA) lysis buffer (RIPA buffer for cell lysis R0278-
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50ML Lot# SLBQ9770V) was added, supplemented with 1% protease inhibitor (Protease 
inhibitor cocktail P8340-1ML Lot# 095M022V) and 2% phosphatase inhibitor (Phosphatase 
Inhibitor Cocktail 2 P5726-1ML Lot# 076M4056V). The amount of lysing buffer used 
depended on the confluence of the cells and for a single well of 6-multi well plate could have 
varied between 100-120μl. After lysing, the cellular monolayer was scratched, off and 
proteins were transferred to Eppendorf tube to be then stored at -80°C. 
Protein quantification: bicinchoninic acid protein assay 
Bicinchoninic acid (BCA) protein assay kit (ThermoFisher Cat# 23228) was used to quantify 
the amount of protein present within the CP-derived cellular lysates. The BSA was used as 
albumin standard (LOT# PH 206816 Prod# 23209 Stock concentration=2mg/ml), and the 
samples of following protein amounts were prepared: 20µg, 15µg, 10µg, 6µg, 2µg and 1µg in 
distilled water (δH₂O) to yield the total of 10µl as working volume.  
The cellular lysates were thawed on ice until completely liquefied and 5µl of each sample 
were diluted in nuclease-free water (Ambion Nalgene P/N AM9937 L/N 1204133) to a final 
working volume of 10µl.  
All samples together with protein standards were prepared in duplicates in Eppendorf tubes. 
Then, the BCA (ThermoFisher; Reagents A Lot PC199737) and Cu(III) sulphate pentahydrate 
(ThermoFisher; Reagent B Lot # PB198437), which were provided with the BCA protein assay 
kit, were mixed to the ratio of 50:1. Then 190µl of reagent A and B mixture was added to 
each, mixed, and incubated for 30 minutes on a heat block at 37°C. Samples were then 
transferred to a 96 multi-well plate and readings were obtained using spectrophotometer at 
562nm. 
Sample preparation and SDS gel electrophoresis 
Based on the results of protein quantification described in above, the total of 20µg of proteins 
of each sample was mixed with 5µl of laemmli buffer (1mL Glycerol, 1g 10% SDS, 6.25 mL β-
mercaptoethanol, 1mL of 0.5% bromophenol, completed to 10 mL with δH₂O). Before 
loading, the samples were heated to 8 minutes at 99°C to allow the secondary structures 
within the proteins to undergo denaturation. The polypeptide chains were then separated 
based on their molecular weight (MW) only. 
The concentration of acrylamide within the gel (see Table 4) was determined based on the 
size of the protein of interest samples were run in freshly prepared running buffer (BioRAD 




Figure 14: Principle of gel electrophoresis for western blotting. Proteins are denatured 
producing a single polypeptide chain, which is then covered with a negative charge. The 
electric potential difference is then generated between anode and cathode, inducing 
polypeptide migration under constant electrical pressure, separating proteins based on the 
size of their polypeptide chain. 
Ref 161-0772) for 20 minutes at a constant electromotive force of 60V, following by ~2 hours 
at 120V. This allowed proteins to be separated based on their MW (see Figure 14). 








δH₂O (ml) 3 3.7 3.4 
30% acrylamide (ml) 0.67 2.13 2.4 
Tris (0.5M pH6.8) 1.25ml N/A N/A 
Tris (1.5M pH8.8) N/A 2ml 2ml 
10% SDS (µl) 50 80 80 
10% APS (µl) 50 80 80 
TEMED (µl) 5 8 8 
Total (ml) 5 8 8 
 
Wet transfer and membrane blocking 
After proteins within samples of nCPs and aCPs were separated based on their MW, they were 
transferred to 0.45μn PVDF Membrane (BioRAD Immuno-blot PVDF Transfer Membrane for 
Protein Blotting Cat# 162-0177). First, this membrane was activated by washing successively 
for 1 minute in methanol (Fisher Chemical Code M13950117 Lot 1714475), 5 minutes in δH₂O 
and 10 minutes in transfer buffer.  
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The transfer sandwich was prepared and run at a constant current of 250mA for 1 hour at 
4°C. After the transfer, the PVDF membrane with proteins attached was washed successively 
for 10 minutes in Tris-buffered saline (TBS) and for another 10 minutes in TBST (TBS +0.05% 
Tween 20). The membrane was then blocked for 1 hour in the freshly-prepared 5% fat-free 
milk (Asturiana Leche en polvo Desnatada) in TBST.  
PVDF membrane incubation with antibodies 
Primary antibodies (mouse anti-human PDGFR-α 1:500, NG2; or β-Tubulin (Loading Control 
Abcam AB6046)) were diluted in 5% fat-free Milk in TBST and incubated ON at 4°C. The 
following morning membranes were washed twice with TBST and TBS for 5 minutes each 
time. Then the membranes were incubated for one hour with secondary sheep anti-mouse 
antibodies conjugated to HRP (GE Sheep anti-mouse IgG Horseradish peroxidase-linked 
NA931V Lot 9850216 LNA931V1AH). After one hour incubation, the membranes were again 
washed twice with TBST and TBS for 5 minutes each time to remove all unbound antibodies 
from the membranes.  
Chemiluminescent antibody detection  
In order to detect the presence of protein recognised by antibodies, the luminol solution and 
hydrogen peroxide (GE Healthcare Amersham ECL Prime Western Blotting Detection Reagent 
Solution A and B RPN2232) solutions were mixed to the ratio of 1:1 and 1ml of the mixture 
was used per each membrane. The membranes were washed for of 5 minutes and then placed 
onto the sample tray of the ChemiDoc MP Image System (BioRAD 170-8280) controlled by 
Image Lab™ Software 6.0. The oxidation of luminol was catalysed by HRP to yield a 
chemiluminescent signal which was detected as a bands developed on the membranes. The 
images of bands were then obtained and exported using Image Lab™ Software 6.0.  
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 Functional characterization 
 
The average cell population doubling times (CPDTs) were determined per nCPs and aCPs 
group. For each cell line used, thirty wells of 96 multi-well plate were seeded with the total 
of three thousand cells. These cells were incubated in 150µl of complete EGM-2 media at 
37°C. The number of cells within wells were counted at six different time points: 24, 48, 72, 
96, 144 and 192 hours. Five replicates were used per each time point for all cell lines. The 
number of cells at each time point was determined by staining cells with Hoechst (diluted at 
ratio 1:2000 in EGM-2 media) for 1 hour at 37°C. After 1 hour the cells were washed with 
DPBS and 150µl EGM-2 media were added per each stained well.  
The fluorescent cells were then visualised by exciting nuclei with UV light with ZEISS 
microscope. The images were obtained using the ZEN Pro Software and the results were 
interpreted with ImageJ Software Automatic cell counter plug-in.  
 
Matrigel (DB Matrigel by Corning® REF 354234 Standard Formula) was stored at -20°C when 
was not in use to avoid early protein polymerization. The day before the experiment, the tube 
with frozen matrigel would be transferred to a fridge to allow ON thawing at 4°C. At the same 
time all other equipment that would come in contact with liquefied matrigel were also placed 
in fridge. The following day the wells of 96 multi-well plate to be seeded with cells were 
carefully coated with 48µl/well of matrigel to avoid any bubbles. The place was then placed 
in an incubator for 30 minutes to allow matrix polymerization. 
Human coronary artery endothelial cells cultured in CP-derived conditioning media 
The potential effect of nCP and aCP-derived CM to enhance angiogenesis was studied. Human 
CAECs (see section 2.2) were seeded on polymerised matrigel at the density of 8,000 cells per 
well. The media lacking CP-derived CM was defined as unconditioned media (UCM) for this 
experiment. The cells were cultured in the 100μl of media composed of 50μl of CP-derived 
CM and 50µl of ECGM (see Figure 15), both referred to as UCMs. The experiment was 
performed in technical triplicates and CAECs cultured on matrigel in the media composed of 
50μl of ECGM and 50µl of EBM-2 or 100μl of ECGM alone were used as negative controls. 
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After seeding the plate was incubated at 37°C for 24 hours. The images of the cellular 
networks were taken at: 3, 5, 8 and 24 hours post seeding.  
 
Figure 15: Schematic representation of the arrangement of samples and controls. Pink: 
CAECs cultured in CP-derived conditioned media, nCPs (CP2, CP16, CP21); aCPs (CP22, CP24, 
CP25). Light blue: CAECs negative control (cell cultured in ECGM and EBM-2 at the ratio 1:1). 
Dark blue: CAECs negative control (cells cultured in ECGM media alone)  
Adult cardiac pericytes (aCPs), endothelial cells growth basal medium (EBM-2), endothelial 
cell growth medium (ECGM), coronary artery endothelial cells (CAECs), newborn cardiac 
pericytes (nCPs). 
Human coronary artery endothelial cells co-cultured with human cardiac pericytes 
The potential variability between nCPs and aCPs to directly participate in angiogenesis was 
studied. As described at the beginning of subsection 2.5.2, the plates were coated with 48μl 
of matrigel and allowed to polymerase at 37°C 5%CO₂ for at least 30 minutes. CPs were 
seeded to CAECs in the ratio of 2:5 as previously described for CPs and Human Umbilical Cord 
Endothelial Cells (HUVEC) co-culture (Avolio, et al., 2015 (a)). However, based on the results 
of optimization experiments, the absolute number of cells per each well was increased by 
50%. Hence the final number of  cells were 3,000 for nCPs and aCPs and 7,500 CAECs per well. 
CAECs seeded alone in EGM-2 and ECGM medium were used as negative controls. Plates were 
incubated at 37°C for 24 hours. The images of the cellular networks were taken at 3, 5, 8 and 
24 hours post seeding. 




The paediatric CPs were tested before for their ability to grow from a single cell to form 
colonies (Avolio, et al., 2015 (a)). The clonogenic capacity of aCPs was never previously 
investigated. Adult cell line CP24 was used for this experiment and cells were seeded at P2 in 
two well of 6 multi-well plate, cultured in EGM-2 allowing to reach confluence. Once 
confluent cells were trypsinized, counted and the solution of 150,000 cells were prepared in 
300μl of fluorescence-activated cell sorting (FACS) buffer (1% BSA (Sigma Aldrich LOT# 
SLBR0685V) with 1mM EDTA (Ambion The RNA Company P/N:AM9260G LN:1509002) in DPBS 
(GIBCO by Life Technology LOT#: 1870721)).  
Fluorescent activated cell sorting 
Cell sorting was performed by Lorena Sueiro Ballesteros (University of Bristol, School of 
Biochemistry) at the FACS facility. Four plates of 96-multi-well plate were used in total for 
single cell sorting. Sixty well per each 96 multi-well plate were filled with 150μl of complite 
EGM-2. The total of 239 wells were seeded with a single CP24 cell each, together with one 
positive control, were 100 cells seed in total. The plates were incubated at 37°C 5%CO₂ for at 
least two week under normoxi conditions in order to allow colony formation. 
 
Three nCPs and aCPs were used to test their capacity to transdifferentiate to VSMCs in 
response to external stimulus. Pericytes were cultured at 37°C 5%CO₂ for two weeks in 
inducive media, which was changed every three days. This media was composed of DMEM 
(Gibco by Life Technology REF#31885-023 Lot#1791397) and MCDB-201 (Sigma Aldrich 
M6770) mixed to ratio of 3:2, supplemented with 1mg/ml linoleic acid-BSA (Sigma-Aldrich 
L9530), 0.0001M ascorbic acid-2 phosphate (Sigma-Aldrich 113170-55-1), 5g/ml insulin, 
5g/ml transferrin and 30nM sodium selenite (Insulin-Transferrin-Selectin by Sigma-Aldrich 
I1884), 2% FBS, 1% Pen/Strep and 2ng/ml human tissue growth factor-β1 (TGF- β1) 
(PeproTech Cat# 100-21).  
Following transdifferentiation antigenic properties (refer to subsection 2.3.2) of newly 
formed cells were compared to the baseline CPs which they were derived from. Additionally, 
the results were compared to commercially available aortic SMCs (see appendix 1).  
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 Statistical analysis 
The results of the quantitative tests for each age group were expressed as mean ± standard 
error of a mean (SEM). Due to the low sample size (maximum of 3 samples per group) Non-
parametric statistical analyses were used.  
The results of ICC were analysed with the Mann-Whitney test.  
For matrigel co-culture angiogenic assays, both aCPs with CAECs, and nCPs with CAECs were 
compared to CAECs alone, using Kruskal-Wallis test followed by Dunn’s multiple comparison 
test to compare the fold change of network length. For matrigel angiogenic assay 
investigating the effect of CP-derived CMs the total length of tubes formed by CAECs was 
analysed. The length of tubes formed by CAECs incubated under different conditions (nCP-
derived CM/aCP-derived CM/UCM) with the Kruskal-Wallis and then with Dunn’s Multiple 
Comparison.  
The differences between the results of two age groups for ICC and ELISA experiment were 
analysed using an unpaired Mann-Whitney test.  
For all statistical analyses, a P-value of <0.05 was used for results to be considered significant. 
All statistical analyses were performed with GraphPad 7.00 Software. 
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Chapter 3  Results: baseline antigenic characterization of cardiac 
pericytes 
 Morphology of isolated CPs 
CP cell lines were isolated from tissue samples based on CD34-positive and CD31-negative 
sorting. These cells were expanded, and their morphology was observed using an optical 
phase contrast microscope. CPs of both age groups were observed to present the typical 
spindle-shaped morphology upon co-culturing in vitro (see Figure 16 A and B) as described 
before (Avolio, et al., 2015 (a)). For all the experiment described below the cells were 
expanded up to P5 or P6 unless otherwise specified. During every expansion procedure, 
cellular morphology was examined under the microscope before cells would be passed for 
further experiments. 
 
Figure 16: Representative phase-contrast microscopic images of nCPs and aCPs. The cells 
were presenting spindle-shaped morphology when observed under the microscope.. 
A: Newborn CP2 5X and 10X magnification.  
B: Adult CP24 5X and 10X magnification. Scale bar: 500µm   
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 Antigenic characterization of baseline CPs  
The baseline phenotype of the CP cell lines was used to study the variation of protein 
expression between aCPs (n=3) and nCPs (n=3). Cells were seeded in the wells upon reaching 
P4 or P5 and the staining was performed on P5 or P6 respectively. The cells were not 
characterised at an earlier passages due to the their limited number available. Furthermore 
these cell lines were also involved in other projects and so the decision was made to perform 
original characterisation on a higher passage to ensure sufficient amount of cells to be 
produced.  
The antigenic characterization was performed as described in section 2.3. Commercially 
available cardiac residential cells: aortic SMCs, CVFs and CAECs (see appendix 1) were used as 
positive controls. Stained cells were analysed using a Zeiss fluorescent microscope and images 
of the cells were taken at either 200X or 100X magnification for qualitative and quantitative 
analyses respectively. To quantify, a semi-automatic cell counting plug-in on the ImageJ 
software package was used to count the cells on images taken at 100x and the mean was 
calculated from the count from 5 images. The images were analysed with semi-automatic cell 
counter plug-in available for ImageJ software.  
The fraction of positive cells was determined by calculating the proportion of target protein 
expressing cells from the total cell count. Subsequently, age-associated variability was 
determined by comparing the proportion of positive cells for nCPs (CP2, CP16, and CP21) to 
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aCPs (CP22,CP24, and CP25). Based on quantitative results the graphs were generated in 
PRISM software and the same application was used for statistical analysis of the results.  
All cell lines were tested for the expression of pericyte markers (NG2, PDGFR-β, CD34 and 
CD146) (see Figure 17 A and B), stemness factors (NANOG, OCT4, SOX2) (see 
 
Figure 18 A), progenitor cell markers (GATA4, PDGFR-α) (see Figure 19 A), endothelial 
markers (CD31 and VE-Cadherin) (see Figure 20 A), intermediate filaments (Vimentin) (see 
Figure 21 A), and extracellular matrix components (intracellular and extracellular collagen 
type I and fibronectin) (see Figure 22). All cell lines showed consistent results with no major 
outliers, which was assessed qualitatively. 




Figure 17: Immunofluorescent characterization of perivascular/mesenchymal cell markers expression by baseline nCPs and aCPs. 
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A: Representative fluorescent images of NG2 and PDGFR-β surface marker expression by nCPs (CP16) and aCPs (CP22). Red arrows indicate 
representative cells negative for marker tested and green arrow indicate positive cell. Nuclei of the cells were stained with HOECHST (blue) and 
the protein of interest was visualized through binding of secondary antibody conjugated to Alexa Fluor 488 dye (green). Scale bar: 100!" 
B: Representative fluorescent images of CD34 and CD146 surface marker expression by nCPs and aCPs. Red arrows indicate representative cells 
negative for marker tested and green arrow indicate positive cell. Nuclei of the cells were stained with HOECHST (blue) and the protein of interest 
was visualized through binding of secondary antibody conjugated to Alexa Fluor 488 dye (green). Scale bar: 100!" 
C: Vertical bar graphs representing the percentage of cells positive for the markers tested. Data are expressed as mean ±SEM (n=3). nCPs are 
indicated with blue colour and aCPs with red colour. No significant difference was identified between nCPs and aCPs  
Adult cardiac pericytes (aCPs), newborn cardiac pericytes (nCPs), neural glial antigen -2 (NG2), platelet derived growth factor receptor beta 
(PDGFR-beta). 
  




Figure 18: Immunofluorescent characterization of stemness markers expression by 
baseline nCPs and aCPs. 
A: Representative fluorescent images of SOX2 and OCT4 and NANOG expression by nCPs and 
aCPs. Nuclei of the cells were stained with HOECHST (blue) and the protein of interest was 
visualized through the binding of secondary antibody conjugated to Alexa Fluor 488 dye 
(green), however for better visualization, the colour was changed from green to yellow using 
ImageJ software. Red arrows represent example of cells negative for marker tested and green 
arrow indicate positive cell. Scale bar: 50!" 
B: Vertical bar graphs representing the percentage of cells positive for marker tested. Data 
are expressed as mean ±SEM (n=3). nCPs are indicated with blue colour and aCPs with red 
colour. Red arrows represent example of cells negative for marker tested and green arrow 
indicate positive cell. No significant difference was identified between nCPs and aCPs (Mann-
Whitney NANOG P>0.999, OCT4 P=0.7 SOX2 P=0.200) 
Adult cardiac pericytes (aCPs), newborn cardiac pericytes (nCPs), homeobox nanog (NANOG), 
octamer-binding transcription factor 4 (OCT4), sex determining region Y-box 2 (SOX2)  




Quantitative assessment of pericyte marker expression of aCPs were compared to nCPs to  
assess for potential variability. NG2 and PDGFR-β markers were abundantly expressed by 
nCPs and aCPs (see Figure 17 A). Meanwhile, CD34 and CD146 were practically undetectable 
in all six CP lines (see Figure 17 B).  
The quantitative assessment of NG2, PDGFR-β, CD34 and CD146 marker expression by nCPs 
and aCPs (see Figure 17 C) confirmed consistency of pericyte marker expression despite the 
age difference.  
The expression of PDGFR-beta was detected on the surface of almost all nCPs and aCPs 
(appeared >99% for both). The variation in the level of receptor expression between newborn 
and adult cells was not significant (P>0.9999), and based on qualitative assessment the 
distribution of this receptor appeared even across the entire surface of the cells tested. The 
expression of NG2 proteoglycan appeared to be lower in aCPs (above 80%) compared to nCPs 
(above 99%), however, the expression was still very high for both and the P=0.4. On the other 
hand, both nCPs and aCPs appeared generally negative for CD34 and CD146. The quantitative 
analyses indicated the level of expression of the two CD markers to be below 5% for both age 
groups. Similarly to NG2 and PDGFR-β the variability of CD34 and CD146 expression between 
nCPs and aCPs were not significant based on P-values (CD34 P=0.1 and CD146 P=0.8).  
 
To investigate potential age-associated changes in the cellular potency and plasticity the 
expression of stemness markers NANOG,OCT4 and SOX2 were analysed and compared 
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between newborn and adult cells (see 
 
Figure 18 A). Based on quantitative analyses the expression of NANOG and OCT4 TFs was 
above 70% for both nCPs and aCPs. However, the quantification of third factor SOX2 
suggested higher variability. While aCPs still presented expression above 70% for SOX2, the 
percentage of nCPs positive for the same TF was only 56%. However based on based on Mann-
Whitney test the variability between the two age groups for all three markers tested was not 
significant (NANOG P>0.999, OCT4 P=0.7 SOX2 P=0.200). 
 
To further analyze the potential age-associated decrease in CPs potency, the expression of 
progenitor cell markers GATA4 and PDGFR-α were tested (see Figure 19). Based on the results 
of qualitative assessment the expression patterns of both markers by nCP and aCP cells were 
quite consistent with no outliers were observed (see Figure 19 A).  
Above 50% of newborn and adult cells appeared positive for GATA4. Furthermore, the 
variation in the level of TF expression between nCPs and aCPs was not significant as 
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determined by Mann-Whitney test (P=0.4). Likewise, the difference in the expression of 
PDGFR-α between nCPs and aCPs was not significant (P=0.4) and the mean percentage of 
positive cells was above 80% for both of both age groups (see Figure 19 B).  
 
Figure 19: Immunofluorescent characterization of progenitor cell marker expression by 
baseline nCPs and aCPs. 
A: Representative fluorescent images of Gata4 and PDGFR-α marker expression. Nuclei of the 
cells were stained with HOECHST (blue) and the protein of interest was visualized through the 
binding of secondary antibody conjugated to Alexa Fluor 488 dye (green).Red arrows present 
example of cells negative for marker tested and green arrow indicate positive cell. Scale bar: 
100!" 
B: Vertical bar graphs representing the percentage of cells positive for marker tested. Data are 
expressed as mean ±SEM (n=3). nCPs are indicated with blue colour and aCPs with red colour. 
No significant difference was identified between nCPs and aCPs (Mann-Whitney GATA4 P=0.4, 
PDGFR-α P=0.4). 
Adult cardiac pericytes (aCPs), newborn cardiac pericytes (nCPs), GATA binding protein 4 
(GATA4) and platelet derived growth factor receptor alpha (PDGFR-α). 
 
Pericytes in vivo occur in close proximity to EC, however, the two cell types have fundamental 
differenced both in terms of cell ontogeny and marker expression. Newborn and adult cells  
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isolated from human tissue based on previously described protocol (Avolio, et al., 2015 (a)) 
are believed to be of mural nature, and so should be negative for endothelial cell markers. 
Due to the close proximity of pericytes to ECs, it was important to test these cells for the 
expression of endothelial cell markers (see Figure 20 A) despite the initial CP isolation was 
based on CD31 negative sorting (see section 2.1).  
 
Figure 20: Immunofluorescent characterization of endothelial cell marker expression by 
baseline nCPs and aCPs. 
A: Representative fluorescent images of CD31 and VE-Cadherin marker expression. Nuclei of 
the cells were stained with HOECHST (blue) and the protein of interest was visualized through 
the binding of secondary antibody conjugated to Alexa Fluor 488 dye (green). Red arrows 
present example of cells negative for marker tested and green arrow indicate positive cell. 
Bar scale: 100!". 
B: Vertical bar graphs representing the percentage of cells positive for marker tested. Data 
are expressed as mean ±SEM (n=3). nCPs are indicated with blue colour and aCPs with red 
colour. No significant difference was identified between nCPs and aCPs (Mann-Whitney CD31 
P>0.99 and VE-Cadherin P=0.7) 
Adult cardiac pericytes (aCPs), newborn cardiac pericytes (nCPs), vascular endothelial 
cadherin (VE-Cadherin). 




Figure 21: Immunofluorescent characterization of type 3 intermediate filament Vimentin 
expression by nCPs and aCPs. 
A: Representative fluorescent images of Vimentin expression. Nuclei of the cells were stained 
with HOECHST (blue) and the protein of interest was visualized through the binding of 
secondary antibody conjugated to Alexa Fluor 488 dye (green).Red arrows present example 
of cells negative for marker tested and green arrow indicate positive cell. The absence of red 
arrows indicate no cells presented on image are defined as negative. Scale bar: 100!". 
B: Vertical bar graphs representing the percentage of cells positive for marker tested. Data 
are expressed as mean ±SEM (n=3). nCPs are indicated with blue colour and aCPs with red 
colour. No significant difference was identified between nCPs and aCPs (Mann-Whitney 
P>0.9999). 
Adult cardiac pericytes (aCPs), newborn cardiac pericytes (nCPs). 
Both CD31 and VE-Cadherin are characteristic surface markers of ECs and are involved in 
tissue integrity, and recruitment of leukocytes from the circulation to the local tissue (Muller, 
et al., 1993). Individually, presentation of these markers are not exclusive to ECs, however 
high co-expression has been associated with ECs, but not pericytes (Martin-Padura, et al., 
1995). The qualitative analyses of CD31 and VE-Cadherin stainings (see Figure 20 A) suggest 
no major age dependent variation in cell phenotype between nCPs and aCPs. There were 
however observed small fractions of CD31 and VE-cadherin positive cells within both age  




Figure 22: Immunofluorescent characterization of extracellular matrix proteins expressions 
by nCPs and aCPs . Representative fluorescent images of intracellular and extracellular 
expression of collagen type I and fibronectin. Nuclei of the cells were stained with HOECHST 
(blue) and the protein of interest was visualized through binding of secondary antibody 
conjugated to Alexa Fluor 488 dye (green).Red arrows present example of cells negative for 
marker tested and green arrow indicate positive cell. Scale bar: 50!". 
Adult cardiac pericytes (aCPs), newborn cardiac pericytes (nCPs) 
groups. The quantitative analyses indicated that the level of CD31 expression to be just above 
5% for both nCPs and aCPs. In the case of VE-Cadherin marker, the fraction of positive cells 
within nCPs population was above 5%, while aCPs had shown expression of this surface 
marker to be below 5%. Statistical analyses found no significant difference in the level of 
either of the two endothelial marker expressions between nCPs and aCPs (CD31 P>0.99 and 
VE-Cadherin P=0.7). 




Vimentin is the type III intermediate filament and is often referred as additional pericyte 
marker. However it also is the most widely distributed cytoskeletal intermediate filament and 
is found in a wide range of cells of the human body. It is both associated with internal 
organelle position and acts as a link between cytoplasm and transmembrane receptors 
(reviewed in (Hol & Capetanaki, 2017)). The fluorescent images of vimentin staining (see 
Figure 21 A) allow highly organised filaments to be visualized for both nCPs and aCPs. The 
qualitative analyses suggested the staining of all six CP cell lines for vimentin to be very similar 
despite the age of origin. Based on quantitative analyses, all nCPs and aCPs appeared to 
express vimentin and not a single cell was identified as negative during tests performed. 
Based on the Mann-Whitney test, there was no significant difference in the pattern of 
vimentin expression between newborn and adult cells (P>0.9999). 
 
Finally, the cells were tested for the production and secretion of the extracellular matrix 
(ECM) proteins: collagen type I and fibronectin (see Figure 22). Collagen type I is the major 
component of the cardiac ECM, whilst fibronectin is a glycoprotein that forms links between 
surface proteins integrins and other ECM components including collagen, fibrin and heparin 
sulphate proteoglycans(reviewed in (Lockhart, et al., 2011)). The importance of pericyte 
ability to secrete ECM components, has been shown to associate with tissue homeostasis as 
well as response to tissue damage and contribution to repair and potentially regeneration 
(Armulik , et al., 2010). The fluorescent images of visualised ECM components were obtained 
for permeabilised and non-permeabilised cells. Based on qualitative analyses, both nCPs and 
aCPs produced ECM protein components. Under either condition there was a high expression 
of ECM matrix components by both newborn and adult cells based on qualitative assessment, 
suggesting both cell types synthesize and secrete collagen and fibronectin in vitro. 
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Chapter 4  Results: western blotting 
During ICC analysis (see section 3.2), the intensity of fluorescent luminescence was 
inconsistently weak for some markers tested, even amongst cell lines from the same age 
group. This could imply large variation in the level of protein expression. As a pilot 
experiment, further analyses were performed in order to validate results from the ICC-IF test 
for some of the major pericyte markers (see subsection2.4.2). 
Three proteins were tested in total: PDGFR-b, PDGFR-α and NG2 as the ICC-IF stainings for 
these markers produced inconclusive results due to variable luminescent signal intensity. In 
total three CP cell lines were used: two paediatric CP5 and CP21 and one adult CP24.  
However, as a pilot experiment, no conclusion was made based on the results due to limited 
number of samples used. Furthermore, because of shortage of samples, the CP5 was included 
in this experiment.  
 Protein quantification  
Before protein expression could be further tested using the western blotting approach, the 
BCA assay was performed to determine the total protein concentration present in the 
samples prepared.  
Table 5: Experimental data of standard protein (BSA) OD at 570nm. The values were 
obtained from the BCA standard assay. For each known concentration of standard protein, the 
average OD at 570nm was measured in duplicates. The actual OD was then determined by 
subtracting blank from the average OD.  
mass of BSA 
(μg) O#$%&1 O#$%&2 O#$%&average 
average O#$%& - 
Blnk 
0 0.092 0.092 0.092 0 
1 0.136 0.124 0.13 0.038 
2 0.201 0.195 0.198 0.106 
6 0.436 0.426 0.431 0.339 
10 0.608 0.608 0.608 0.516 
15 0.864 0.843 0.8535 0.7615 
20 1.08 1.059 1.0695 0.9775 
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The cellular lysates were produced as described in subsection 2.4.2 and then the 
concentrations of the proteins within the solution of each sample were determined using a 
BCA protein assay.  
Based on the results of the BCA assay, the standard curve was generated by plotting the 
concentration of BSA against its OD at 570nm (see Table 5). From the graph, the relationship 
between the concentration of protein standard and its OD of the solution at 570nm was 
described as linear. Based on the value of Pearson’s correlation coefficient (R²=0.9973), the 
relationship between light absorption and protein concentration fits well with the equation 
of the straight line. Hence this equation could be applied to estimation the concentrations of 
proteins within cellular lysate of the samples.  
 
Figure 23: BSA assay standard curve. Concentrations of protein standard were plotted against 
OD value determined experimentally by measuring the absorption of solution 570nm. The 
graph presents a linear relationship described by the equation: y=0.0495x+0.0093. R-value 
also describes the strong positive correlation between OD and BSA concentration. 
Equation 1 
' = 0.0495. + 0.0093 
In the equation above x-value and y-values represent the concentration of the protein and 
OD-value at 570nm respectively.  
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The OD of the samples tested were measured in parallel with the OD of the BSA protein 
standards. Unlike the protein standard, the concentrations of proteins within CP samples 
remained unknown. Hence in order to determine the concentration of the proteins within the 





Now the equation above (equation 2) could be applied to the experimental data, to identify 
the total concentration of proteins within samples tested.  
Consider the following example: 
In order to determine the concentration of proteins in the cellular lysate of CP5, the following 
manipulations were performed: 
Equation 3 
234567	9:	(6<6	2=>?6@>	9: − A76B<) = 0.3615 − 0.092 
234567	9: = 0.2695 





. = 5.26 
The equations and calculations above enable us then to determine the actual amount of 
proteins present in 5µl of cellular lysates.  
In the western blotting experiments, 20μg of protein were loaded per for cell line. The volume 





2"G5B4	GH	K?G4>JB	JB	157 = 1.055@ 
Hence, the volume of cellular lysate containing 20μg of protein (CP5 for the calculations 
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LG75">	GH	MI5	3>77	7'N64>	3GB46JBJB@	205@	GH	K?G4>JB = 19.0257 
 
Table 6: Measurement of OD of protein lysates at 570nm and calculation of protein 
concentration. In total three cell lines were used, the newborn CP21, infant CP5 and adult 
CP21. Data were obtained and measured in duplicates. Values were based on actual OD values 
and obtained by subtracting blank from average OD. The total amount of protein present in 
5µl was calculated from the equation obtained from the standard curve and presented for 
each sample in the following table. 
Cell Line OD1 OD2 Average OD 










CP5 0.357 0.366 0.3615 0.2695 5.26 19.02 
CP21 0.376 0.359 0.3675 0.2755 5.38 18.6 
CP24 0.391 0.333 0.3620 0.2700 5.27 18.99 
The calculations performed for CP21 and CP24 were identical to the one described above for 
CP5 with respect to specific ODs. For each cell line used in this experiment, the volume of the 
cell lysate containing 20μg of protein was calculated based on its OD (see Table 6) applied to 
the equation derived from the BSA standard curve (see Figure 23).  
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 Western blotting: pericyte markers 
In order to analyse the presence of proteins of interest within cellular lysates, 20μg of proteins 
were loaded for each cell line (refer to the Table 6 for corresponding volumes), together with 
7μl of 6x Loading Buffer and if necessary the addition of δH₂O to make up the final volume to 
42μl per each sample.  
Western blot was performed to further confirm the expression of pericyte markers 
(NG2/CSPG4 and PDGFR-β) and PDGFR-α, these are often recognized as a cardiac or vascular 
progenitor cell marker (Chong, et al., 2013) as well as MSC-marker (reviewed in (Farahami & 
Xaymaradan, 2015)).  
All three proteins tested were of high MW. The electrophoresis was performed in 8% 
separating gel and the proteins were subsequently transferred to a 0.45 µm PVDF membrane 
using wet transfer for further detection.  
 
Figure 24: Result of protein detection in CPs lysates by western blotting. Three proteins were 
tested: NG2, PDGFR-β and PDGFR-α in paediatric (CP5 and CP21) and adult (CP24) samples.  
A. Representative western blot of the PDGFR-α expression in CPs, normalized with β-Tubulin. 
B. Representative western blot for NG2 expression in CPs, normalized with β-Tubulin.  
C. Representative western blot for PDGFR-β expression in CPs, normalized with β-Tubulin 
Adult cardiac pericytes (aCPs), newborn cardiac pericytes (nCPs 
 
PVDF membrane with bound proteins was incubated with anti-PDGFR-α mouse monoclonal 
antibody, which recognising the section of PDGFR-α tyrosine kinase receptor containing the 
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951-1089 amino acids (Santa Cruz datasheet). Upon incubation, the clear signal was detected 
for only one of the two paediatric CPs tested, the infant sample CP5, while CP21 sample 
presented no band for PDGFR-α. The adult sample CP24 developed only a very weak band 
(see Figure 24 A), which suggested either low receptor expression or weaker recognition by 
the antibody. Based on the position of bands, the MW of polypeptide recognized was about 
170kDa, which correspond to the predicted size of the receptor (as stated by antibody 
manufacturer). 
The only newborn cell line tested CP21 presented no signal implying no detection performed 
by a monoclonal antibody (see Figure 24 A). These findings oppose the results of ICC-IF 
performed on the cells earlier (section 3.2), which suggested that all cell lines tested were 
PDGFR-α positive, including CP21. Furthermore, both experiments were performed with the 
same antibody. The most obvious explanation for such a result could be the amount of 
PDGFR-α receptor expressed CP21 to be insufficient for detection. This correlates with the 
fact that the current membrane was exposed for 109s before the proper signal was detected 
for CP5 and CP24. Moreover, based on the qualitative analyses of ICC-IF images for PDGFR-α 
expression, the cells presented a very fade signal. However, the increase in the time of 
exposure of the sensor to light only enhanced non-specific signal interferences, while no 
bands were detected. Alternatively, the PDGFR-α expressed by CP21 had a high MW than had 
been originally predicted, the protein could have simply failed to transfer to PVDF membrane, 
hence it could not be detected due to its absence.  
 
The same membrane that was used for PDGFR-α detection was also used for detecting NG2 
protein (see Figure 24 B). The membrane was washed then incubated with rabbit anti-human 
NG2 polyclonal antibody. The antibody used for NG2/CSPG4 identification was a polyclonal 
antibody with multiple regions/epitopes of recognition. Hence, antibody could recognize both 
the intact proteoglycan as well as the core protein.  
Naturally, the average size of NG2 protein appearing on the gel can vary between 200-300 
kDa. Additionally, the NG2 core protein has glycosylation sites and three glycosaminoglycan 
attachment sites. The MW of the resulting transmembrane proteoglycan can exceed 500kDa 
(Girolamo, et al., 2013). Both glycosylation and GAG-attachment sites are post-translational 
modifications, so influence level of protein expression, localization, MW, and possibly 
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signalling. The type of NG2 isoforms and glycoforms expressed depends on the type of cell or 
the conditions surrounding the cell (Ampolo, et al., 2017). 
In terms of the pericytes, it was documented before that the pattern of NG2 expression varies 
between arteriolar (NG2-positive) and venous (NG2-negative) pericytes of mesenteries, while 
the retinal pericytes appear to be NG2 positive despite their microvascular subset (Alon & 
Nourshargh, 2013) (Murfee, et al., 2005) (Chan-Ling & Hughes, 2005).  
Based on the datasheet provided by antibody manufacturer the predicted size of NG2 was 
supposed to be between 270-300kDa. Incubation of membrane with antibody yield (see 
Figure 24 B) two distinct bands of ~130 and ~70kDa for each of the three CP-lines tested. 
Based on qualitative assessment the bands appeared similar between all the cell lines tested 
suggesting consistent expression of NG2. The presence of more than one band on the 
membrane could be explained by the polyclonal nature of the antibody. The bands developed 
on the gel could have been the intracellular proteolytic fragments from protein digestion. 
Such rationale correlates with the fact that both bands present on the membrane were of 
lower MW than expected. As the membrane was exposed for 153 seconds, the fragments 
detected did not appear to be very abundant inside the cell.  
The absence of high molecular band suggests unsuccessful NG2 detection. Presumably, 
protein failed to migrate from the gel due to large size. Alternatively, the initial amount of 
antigen presented within the cell could have been insufficient first-hand. This correlates with 
ICC-IF results (section 3.2), as both nCPs and aCPs had appeared weakly positive for NG2 
expression, based on qualitative analyses. Finally, the same membrane was used before for 
protein detection, so some of the protein could have been washed off before the antibody 
was introduced.  
 
The final test was performed to determine the expression of PDGFR-β surface protein (see 
Figure 24 C). This protein was predicted to be of a high MW as well, so the electrophoresis 
was performed in 8% separating gel. The proteins were then transferred to the 0.45µm 
membrane using wet transfer and incubated with mouse anti-human PDGRF-β monoclonal 
antibody.  
Anti-PDGFR-β antibodies used were rabbit polyclonal antibodies raised against C-terminus 
peptides of the human PDGFR-β receptor (purchased from Santa Cruz). Upon incubation of 
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the membrane with antibody the clear signal was detected for all three cell lines: CP5, CP21, 
and CP24 after just 5.5 seconds of exposure. For each cell line, two bands corresponding to 
higher (~170kDa) and lower (~70kDa) MW fragments appeared on the membrane. The longer 
polypeptides also presented the strongest bands on the membrane of all three samples 
tested.  
Based on the prediction of anti-PDGFR-β antibody manufacturers the higher MW band 
presented on the membrane corresponding to the PDGFR-β receptor. The lower MW bands 
developed of ~70kDa were believed to be intracellular proteolytic fragments. This correlates 
with the fact that the antibodies used were of polyclonal nature and had been raised against 
epitopes around C-terminus. As the strong signals were developed after only 5.5 seconds 
following exposure for both higher and lower MW bands, the level of receptor expression was 
relatively high, especially compared to other proteins tested by western blotting. 
 
Anti-β-Tubulin antibody was used as a housekeeping protein for control of the amount of 
protein loaded. This allowed to perform a qualitative assessment of the relative amount of 
proteins loaded per each sample (see Figure 24 A, B and C: β-Tubulin).   
After the presence of proteins of interest had been tested, the membranes were incubated 
with anti-β-Tubulin antibody –Loading Control. This antibody was used to identify the product 
of the housekeeping gene, β-Tubulin, one of two globular polypeptides. Together with α-
Tubulin they heterodimerization and assemble into protofilaments, composing microtubule 
inside the cells (GM.Sunderland, 2000). The method of normalization is based on the 
assumption that for the samples used, the expression of housekeeping protein would be the 
same.  
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Chapter 5 Results: angiogenic factor production 
 ELISA assay 
The ageing can have a negative effect on the ability of cells to secrete GF (reviewed in (Ellison-
Hughes & Madeddu , 2017)). Hence CPs of two age groups were analysed for the production 
of GFs. The total of six cell lines (nCPs: CP2, CP16, CP21 and aCPs: CP22, CP24 and CP25) were 
used to study the amount of pro-angiogenic GFs: Ang-2, human VEGF, and Ang-1, secreted by 
nCPs and aCPs.  
The CM was collected as described in subsection 2.4.1. and its content was analysed with the 
ELISA assay. 
 
CM was collected from both nCPs and aCPs, and its composition was analysed for the 
presence of Ang-1. CM was collected from the cells after they were subjected to 48 hours of 
starvation. The OD of CM was measured at 450nm (see Table 7). 
Table 7: Measurement of OD of Ang-1 protein standard at 450nm. ODs of protein standards 
of known concentrations were measured in triplicates and the averages were determined for 
each concentration. The OD of reagent diluent was then subtracted from average ODs of 
protein standard to yield the actual ODs of protein standard. The logarithms of resulting values 
were plotted on the graph against a known concentration (see Figure 25).  
standard concentration (ƿg/ml) OD1 OD2 OD3 
Log (Average 
OD-Blank) 
ST1 10000 2.762 2.712 2.668 0.164055 
ST2 5000 2.212 2.145 2.145 -0.02472 
ST3 2500 1.526 1.474 1.481 -0.20528 
ST4 1250 0.943 0.914 0.92 -0.41416 
ST5 625 0.559 0.547 0.542 -0.67435 
ST6 313 0.344 0.332 0.329 -0.94564 
ST7 156 0.224 0.215 0.211 -1.23161 
RD 0 0.099 0.095 0.089 N/A 
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After measuring the OD of Ang-1 protein standard (see Table 7), the logarithm of the resulting 
values were plotted on the graph against corresponding concentrations. The standard curve 
(see Figure 25) was then generated to describe the relationship between the concentration  
 
Figure 25: Angiopoetin-1 standard curve. The equation of the function describing the 
relationship between the concentrations of angiopoetin-1 standard protein and the logarithm 
of OD readings at 450 nm. Based on the R-value of the best-fit line describes well the 
relationship and can be used to determine the concentration of proteins within samples. 
of GF and its OD at 450 nm. The equation produced from the graph hence describing the 
effect of change of Ang-1 concentration (ƿg/ml) on the logarithmic value of the OD measured. 
In our case the equation from the graph (see Figure 25) represented the correlation between 
the logarithm of OD at 450nm and the concentration of the Ang-1 of the sample of interest:  
Equation 7 
' = 0.3272 ∗ ln( .) − 2.4861 
In the equation above (equation 7), the x-value represents the concentration of Ang-1, which 
was present in the solution and y-value corresponded to the logarithmic value of OD. The OD 
represented the absorption of light at 450 nm wavelength. In order to calculate the 
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concentration of Ang-1 in the samples tested, the equation above was rearranged as 
following: 
' = 0.3272 ∗ 7B . − 2.4861 
 
0.3272 7B . = ' + 2.4861 
Table 8: Measurement of OD of CP lysates at 450nm. Three newborns (CP2, CP16, CP21) and 
three adults (CP22, CP24 and CP25) were tested. For each sample tested the OD values at 
450nm were measured in triplicates and then the average values were calculated. The OD of 
reagent diluent was then measured and subtracted from average ODs of CP sample to yield 
the actual ODs of samples. The log values were obtained and applied to the equation derived 
from the standard curve. 
standard OD1 OD2 OD3 Log (average OD-Blank) 
CP2 0.254 0.254 0.25 -0.8106 
CP16 0.267 0.268 0.27 -0.7687 
CP21 0.177 0.173 0.175 -1.11351 
CP22 0.455 0.454 0.471 -0.44129 
CP24 0.308 0.313 0.316 -0.66891 
CP25 0.823 0.809 0.85 -0.13707 
 
' + 2.4861
0.03272 = 7B . 
The rearrangements described above yield new equation shown below (equation 8), 
describing the un-known x-value (concentration of Ang-1 in the sample), as an Euler’s number 
to the power of: sum of constant (2.4861) and corresponding OD value of sample tested (y-





The experimentally obtained ODs of the samples were applied to the equation to calculate 
the concentration of Ang-1 in the nCP and aCP samples. During the procedure, ODs of CM 
(see Table 8) were measured in parallel with ODs of protein standard (see Table 7).The 
experimentally determined values of CPs ODs were then applied to the equation described 
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above (equation 8), in order to calculate the concentration of Ang-1 present in the nCP and 
aCP samples.  
Table 9: Concentration of Ang-1 present in 100 µl of media 







The resulting concentrations of GF calculated, where the amount of Ang-1 present in 100µl 
of CMs, which was produced and secreted by cells grown in the T25 flask during the two days 
of incubation (see Table 9). 
The results were then normalized, with respect to the total cell number in the flask, time of 
incubation and volume of media (see Table 10). The final results were calculated as the 
amount of GF secreted by 100,000 cells in 48 hours.  
Table 10: Incubation conditions and a total number of cells present in the flask. This data 













CP2 445000 48 2.9 
CP16 1215000 49 5.8 
CP21 1432000 48 2.9 
CP22 557000 48 2.9 
CP24 995000 48 2.9 
CP25 790000 48 2.9 
 
Using information presented in Table 10 the concentration of Ang-1 (see Table 9) was 
normalized. The amount of Ang-1 secreted by a hundred thousand cells per hour were found 
to be 1.45ρg and 5.66ρg for nCP and aCP groups respectively (see Figure 26). 




Figure 26: Average amount of Ang-1 secreted by nCP and aCP. The amount was calculated 
pg per hour secrete by 100,000 cells. Data are expressed as the mean ±SEM (n=3) Blue colour 
indicate nCPs (newborn) and red colour indicates aCPs (adult) cells. No significant difference 
was identified between nCPs and aCPs (Mann-Whitney P=0.4) 
Adult cardiac pericytes (aCPs), newborn cardiac pericytes (nCPs). 
According to the statistical analysis performed, the variation in the average amount of Ang-1 
secreted by nCP and aCP cell lines did not appear to be significant (Mann-Whitney test 
(P=0.4). This implies that there is no age-dependent change in the amount of Ang-1 secreted 
by CPs. 
  




Table 11: Measurement of OD of Ang-2 protein standard at 450nm. The ODs of protein 
standards of the known concentrations were measured in triplicates to yield an average. The 
actual ODs of standards were obtained by subtracting OD of reagent diluent form average 
ODs. The logarithms of resulting actual values were plotted on the graph against 
corresponding concentrations (see Figure 27). 
standard concentration  (ƿg/ml) OD1 OD2 OD3 
Log (average 
OD-blank) 
ST1 6000 2.536 2.469 2.466 0.388457 
ST2 3000 1.916 1.872 1.824 0.26158 
ST3 1500 1.282 1.181 1.17 0.066947 
ST4 750 0.734 0.682 0.704 -0.17892 
ST5 375 0.418 0.398 0.402 -0.44169 
ST6 187.5 0.23 0.225 0.227 -0.73755 
ST7 93.8 0.136 0.131 0.129 -1.05716 
 
Figure 27: Angiopoetin-2 standard curve. The equation of function describes the relationship 
between the concentrations of Ang-2 standard protein and the logarithms of its OD readings 
at 450 nm. According to the R-value, the best-fit line describes well this relationship of GF 
concentration and the logarithmic of its OD value. 
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A similar approach described above was used to determine the potential age-associated 
variability in the amount of Ang-2 produced by six different cell lines (nCPs: CP2, CP16, CP21 
and aCPs: CP22, CP24 and CP25) using ELISA assay.  
Logarithmic value of ODs of Ang-2 protein standard was plotted on the y-axis against the 
corresponding concentrations. The function of this relationship (see equation 9) was 
determined from the best fit line and described the relationship well based on its R-value) 
(see Figure 27).  
Equation 9 
' = 0.3526 ln . − 2.5772 
The equation above (equation 9) could then be applied to determine the amount of Ang-2 
produced by six different cell lines studied. Initially, however, the equation had to be re-
arranged. The ODs of samples tested were determined experimentally in parallel with ODs of 
sample standards (see Table 11), while the corresponding concentration (x-value) of nCPs and 
aCPs lysates was yet unknown. In order to determine the Ang-2 concentrations the 
rearrangement was made as following: 









The resulting equation (equation 10), described the un-known x-value (concentration of Ang-
2 in the solution), as an Euler’s number to the power of the sum of constant (2.5772) and the 
logarithm of measured OD value of the samples tested (y-value), divided by constant (0.3526).  
This equation (equation 10) was based on the correlation between Ang-2 protein standard 
concentration and its corresponding OD (450nm) value presented in the graph (see Figure 
27). By applying this equation the average amount of Ang-2 produced by nCPs and aCPs could 
have been calculated and compared. The experimentally obtained OD values (see Table 12) 
of nCPs and aCPs were then applied to the derived equation (equation 10) to calculate the 
concentration of Ang-2 present. 
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Table 12: Measurement of OD of CP lysates at 450nm. Three newborns (CP2, CP16, CP21) 
and three adults (CP22, CP24 and CP25) were tested. For each sample tested, the OD values 
were measured in triplicates and the averages were then determined for each cell line. The 
OD of reagent diluent was then measured and subtracted from average ODs to yield the actual 
OD of samples tested. The log value was obtained from the resulting ODs and those were then 
introduced to the equation to generate a standard curve of the relationship standard curve. 
standard OD1 OD2 OD3 Log (average OD-blank) 
CP2 0.618 0.634 0.605 -0.24058 
CP16 0.226 0.232 0.232 -0.73127 
CP21 1.322 1.313 1.323 0.10551 
CP22 0.243 0.257 0.259 -0.68055 
CP24 0.506 0.502 0.509 -0.33598 
CP25 1.516 1.506 1.501 0.165343 
 
The resulting amount of protein calculated was the amount present within 100µl of CM 
obtained from T25 flask after two days of incubation (see Table 13). 
Table 13: Concentration of Ang-2 present in 100µl of sample 







The resulting concentration (see Table 13) represents the amount of Ang-2 present in the 
100µl of the sample obtained from the confluent T25 flask. Before the average amount of 
Ang-2 produced by different age groups could be compared, the concentrations of GF was 
normalized with respect to the data presented in Table 14.  
Using the information provided in Table 14 as well as the results of Ang-2 ELISA assay (see 
Table 13), the amounts of GF secreted by 100,000 cells per hour were determined for each of 
the six cell lines. The average amount was then calculated for both age group and the resulting 
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Table 14: Incubation conditions and a total number of cells present in the flask. This data 







total time of 
incubation 
(hours) 
total volume of 
media collected 
(ml) 
CP2 445000 48 2.9 
CP16 1215000 49 5.8 
CP21 557000 48 2.9 
CP22 995000 48 2.9 
CP24 717000 48 2.9 
CP25 1085000 48 2.9 
values were compared between each other. Based on the results the average amount of Ang-
2 secreted by a hundred thousand cells per hour were 10.10ρg and 5.76ρg for nCP and aCP 
groups respectively (see Figure 28). 
 
Figure 28: Average amount of Ang-2 secreted by nCPs and aCPs. The amount was calculated 
pg per hour secrete by 100,000 cells. Data are expressed as the mean ±SEM (n=3) Blue colour 
indicates nCPs (newborn) and red colour indicate aCPs (adult) cells. No significant difference 
was identified between nCPs and aCPs (Mann-Whitney P=0.700). 
Adult cardiac pericytes (aCPs), newborn cardiac pericytes (nCPs). 
Despite the fact that based on the experiment the nCPs appeared to secrete almost twice the 
amount compared to aCPs, the Mann-Whitney test performed found no significant difference 
in the amount of Ang-2 between two age groups (P=0.700).  




The secretion of third pro-angiogenic factor hVEGF by CPs was also determined using ELISA 
assay. CMs of  six cell lines of CPs (nCPs: CP2, CP16, CP21 and aCPs: CP22, CP24 and CP25) 
were used. 
The method used was identical to the ones performed before for Ang-1 and Ang-2 (see 
subsections 5.1.1 and 5.1.2). First ,the VEGF protein standards of seven known concentrations 
were used to measure OD of the solution at 450nm (see Table 15).  
The CMs derived from nCPs and aCPs were analysed in parallel with hVEGF sample standards 
provided in the ELISA assay kit and both the samples and standards were measured in 
triplicates.  
Table 15: Measurement of OD of VEGF protein standard at 450nm. ODs of protein standards 
were measured at 450nm in triplicates to yield the average value. The OD of reagent diluent 
was then subtracted from average ODs of protein standard to yield the actual ODs of protein 
standard. The logarithms of resulting values were then plotted on the graph against 
corresponding concentrations 
standard concentration (ƿg/ml) OD1 OD2 OD3 
Log (average 
OD-blank) 
ST1 2000 1.573 1.452 1.486 0.164055 
ST2 1000 0.988 0.97 1.01 -0.02472 
ST3 500 0.726 0.638 0.64 -0.20528 
ST4 250 0.456 0.418 0.416 -0.41416 
ST5 125 0.272 0.246 0.251 -0.67435 
ST6 62.5 0.163 0.154 0.157 -0.94564 
ST7 31.3 0.106 0.103 0.101 -1.23161 
Using experimentally obtained data on the ODs of sample standard solutions (see Table 15), 
the standard curve for the relationship of hVEGF concentration and the log of solution ODs 
was produced (see Figure 29). The equation of relationship was obtained by plotting 
logarithm solutions average OD measured at 450nm on the y-axis against the know 
concentration of the hVEGF standard on the x-axis. The relationship was described well by 
the best fit line according to its R-value (R=0.9793).  
This equation (equation 11) could be used to determine unknown OD by applying known 
protein concentration to the formula: 




' = 0.3272 ln . − 2.4861 
 
Figure 29: hVEGF standard curve. The relationship between change in the concentration of 
hVEGF protein standard in the solution and corresponding logarithmic value of OD at 450nm. 
Based on the R-value the equation for the best-fit line describes well this relationship. 
The OD of CP samples was measured in parallel with ODs of VEGF protein standards. While 
the equation (equation 11) described well the relationship between OD and concentration of 
hVEGF, in order to determine unknown concentration from known solution OD, it was 
rearranged as follows.  




As already discussed the equation obtained from the standard curve (see Figure 29) defined 
y-value as the logarithm of the average OD measured at 450nm and x-value as the hVEGF 
concentration within the sample. Upon re-arrangement of this equation (equation 11), the 
new equation was derived (equation 12), which allowed to calculate the unknown 
concentration of hVEGF for samples of known OD at 450nm (see Table 17). Essentially the 
equation described the concentration of protein as Euler’s number to the power of the sum 
of the logarithm of OD and constant (2.4861) divided by constant (0.3272). 
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Table 16: Measurement of OD of CP lysates at 450mn. Three newborns (CP2, CP16, CP21) 
and three adults (CP22, CP24 and CP25) were tested. For each sample tested the OD values 
were measured at 450nm in triplicates and the average value was determined. The OD of 
reagent diluent was then measured and subtracted from average OD of CP sample to yield the 
actual ODs of samples The log value was obtained from the resulting value and then applied 
to the equation obtained from the standard curve. 
standard OD1 OD2 OD3 Log (average OD-blank) 
CP2 0.361 0.353 0.351 -0.50817 
CP16 0.708 0.716 0.755 -0.16643 
CP21 0.145 0.164 0.16 -0.95208 
CP22 0.58 0.675 0.682 -0.22113 
CP24 0.242 0.254 0.247 -0.6925 





From the equation 12 derived from the best fit line (see Figure 29), the concentration of 
human VEGF secreted by six different CPs were calculated (see Table 17). 
Table 17: Concentration of VEGF present in 100µl of sample 







Before the average amounts of hVEGF secreted by nCPs and aCPs could be compared, 
concentration was normalized based to the cell number, total volume and time of incubation. 
The data presented in Table 18 were used to normalize the GF concentrations. 
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Table 18: Incubation conditions and a total number of cells present in the flask. This data 













CP2 445000 48 2.9 
CP16 1215000 49 5.8 
CP21 1432000 48 2.9 
CP22 515000 48 2.9 
CP24 880000 48 2.9 
CP25 717000 48 2.9 
Hence to determine the amount of the GF secreted by 100,000 cells, the results presented in 
Table 17 were normalised with respect to the data listed in Table 18.  
Finally, the average amount of hVEGF secreted by 100,000 nCPs and aCPs per hour was 
determined for and could be compared (see Figure 30). Based on the calculations the average 
amounts of VEGF secreted were 3.16ρg and 2.73ρg for nCP and aCP groups respectively. 
 
Figure 30: Average amount of VEGF secreted by nCPs and aCPs. The amount was calculated 
in pg per hour as by 100,000 cells. Data are expressed as the mean ±SEM (n=3). Blue colour 
indicate nCPs (newborn) and red colour indicates aCPs (adult) cells. No significant difference 
was identified between nCPs and aCPs (Mann-Whitney P>0.999). 
Adult cardiac pericytes (aCPs), newborn cardiac pericytes (nCPs). 
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The results of the amount of GF secreted by two age groups appeared very similar. The 
statistical analysis (Mann-Whitney test) found no significant difference (P>0.999) between 
the amount of VEGF secreted between nCPs and aCPs.  
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Chapter 6  Results: matrigel angiogenic assay 
Matrigel is a protein mixture obtained from Engelbreth-Holm-Swarm mouse sarcoma cells. It 
mimics complex ECM environment and induces ECs to form complex network structure. Yet 
the newly formed microvasculature is only short-living and usually completely fades off after 
24 hours of incubation. Despite this limitation it allow to study the EC network formation and 
is currently considered the optimal in vitro model available to study angiogenesis (as stated 
by manufacturer BD Bioscience, Matrigel datasheet). 
 Cardiac pericyte co-culture 
In this chapter, the abilities of aCPs as well as nCPs to facilitate network formation by ECs 
were investigated. Previously neonatal CPs were shown to increase the total length of 
networks formed by HUVEC cultured on matrigel (Avolio, et al., 2015 (a)). This indicated the 
ability of neonatal CPs to directly participate in tube formation. However, the pro-angiogenic 
effect of CPs on CAECs was never previously reported, neither was the ability of aCPs to 
participate in network formation.  
In order to further test the potential age-associated variability in pro-angiogenic activity of 
pericytes the six samples (nCP: CP2, CP16 and CP21; aCPs: CP22, CP24 and CP25) were used 
in two individual experiments. The resulting total network lengths formed by CPs co-cultured 
with CAECs after 8 hours of incubation, were presented as a fold change, with CAECs defined 
as a control. The average network length formed by CPs alone or CPs co-cultured with CAECs 
were calculated as fold change of CAECs control. In addition nCPs and aCPs were seeded alone 
as a negative control to highlight that they only contribute to network formation by 
endothelial cells, while they fail to form stable network on their own. 
Both nCPs and aCPs appeared to increase the total length of networks formed by CAECs, as 
seen from the Figure 31 A and B. CAECs incubated alone on matrigel for 8 hours on average 
formed networks of 32.50mm long, while in the presence of nCPs and aCPs the lengths were 
increased 1.41- and 1.43-fold respectively (see Figure 31 B). Furthermore upon reaching 24 
hours both networks that had been formed by co-cultured and controls had faded off.  
Nevertheless the effect of CPs enhancement of network formed by CAECs was assessed in 
terms of age. In order to identify if there was any significant variation between two age 




Figure 31: Results of matrigel angiogenic assay investigating the potential variation of the 
ability of CPs to participate in CAECs network formation, depending on the CPs’ age group. 
A: Representative images of CAECs network formations and disintegrations over the 24-hour 
period in the presence and absence of nCPs and aCPs. Scale bar: 500!" 
B: Vertical bar graphs representing the fold change of the total network length formed by cells 
after eight hours of incubation in relation to control. Data are expressed as mean ±SEM (n=3). 
No significant difference was identified between nCPs and control (Dunn’s multiple 
comparison P=0.1317) while the difference between aCPs and control was significant (Dunn’s 
multiple comparison P=0.0459). Significant difference was denoted with [*]. Black marking 
corresponds to no CPs, blue correspond to nCPs and red to aCPs. 
Adult cardiac pericytes (aCPs), coronary artery endothelial cells (CAECs), newborn cardiac 
pericytes (nCPs). 
groups, the non-parametric One-way ANOVA test was performed. Due to the low number of 
samples within age groups (n=3), the Gaussian distribution could not be assumed, and hence 
the Dunn’s multiple comparison tests were performed with PRISM Software. The resulting 
fold changes in the presence of nCPs and aCPs were compared to CAECs alone (assigned as 
1). Based on statistical analyses only the difference between CAECs and aCP co-culture 
(P=0.0459) appeared significant, while the difference between CAECs alone and co-culture 
with nCPs (P=0.1317) did not.  
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 Coronary artery endothelial cell with cardiac pericyte- derived 
conditioned media  
 
Figure 32:Results of matrigel angiogenic assay investigating the effect of CP-derived 
conditioned media as an enhancer of CAECs network formation. The difference in the 
angiogenic capacity was compared between nCPs and aCPs.  
A: Representative images of CAECs networks formation and disintegration over a 24-hour 
period by CAECs, while those were incubated with/without CP-derived conditioned media. 
Scale bar: 500µm. 
B: Vertical bar graph representing the quantification of the average network lengths formed 
by CAECs after eight hours of incubation with or without CP-derived conditioned media. Data 
are expressed as mean ±SEM (n=3). No significant difference was identified between nCPs 
and control (Dunn’s multiple comparison P=0.2721) while the difference between aCPs and 
control was significant (Dunn’s multiple comparison P=0.0225). Significant difference was 
denoted with [*]. Black marking corresponds to no CP-derived conditioned media, blue 
correspond to nCP-derived conditioned media and red to aCP-derived conditioned media. 
Adult cardiac pericytes (aCPs), coronary artery endothelial cells (CAECs), conditional  newborn 
cardiac pericytes (nCPs) un-conditional media (UCM). 
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The assessment of the pro-angiogenic ability of CP secretome was performed by culturing the 
CAECs with CP-derived CM alone. Six CPs were used in total to produce CMs, including three 
nCPs (CP2, CP16 and CP21) and three aCPs (CP22, CP24 and CP25). The potential pro-
angiogenic effect of factors, cytokines and chemokines secreted by CPs was investigated upon 
culturing CAECs with CP-derived CM on Matrigel.  
Upon incubation of CAECs under different conditions (with nCP-derived CMs, with aCP-
derived CMs or in an UCM), the total length of networks formed by CAECs, on matrigel were 
analysed. Both nCP- and aCP-derived CMs appear to increase the total length of networks 
formed by CAECs, as seen from Figure 32 A and B. The average network length formed by 
CAECs alone was 47.78mm, while in the presence of CP-derived CM was 60.17 and 65.95 for 
nCPs and aCPs respectively following 8 hours of incubation (see Figure 32 B). Furthermore as 
expected the networks did not survive long and following 24 hours had almost disappeared. 
The potential effect of CP-derived CM on the time of tube stability was not investigated.  
To identify whether the variation between the average length of networks formed by cells of 
different age group, appeared to be significant, the One-way ANOVA test was performed. Due 
to low number of samples within age groups (n=3), the Gaussian distribution could not be 
assumed and hence a non-parametric alternative, the Kruskal-Wallis test was used. Based on 
results of Dunn’s multiple comparison tests only aCP-derived CM appeared to significantly 
increase the total network length formed by CAECs when compared to UCM (P=0.0225), while 
the presence of nCP-derived CM had no significant change on the ability of CAECs to form 
networks on matrigel (P=0.2721).  
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Chapter 7  Results: cell population doubling time and clonogenic 
capacity 
 Cell population doubling time 
CPDT of the cell line indicates the time required for cells to double in number  (ThermoFisher, 
2016) and is an important general cell line characteristic. The decrease in the CPDT can be 
associated with cellular ageing as the population of cells can no longer support normal growth 
and proliferation. It was hence essential to determine if there is any variability in the CPDT of 
two age groups tested.  
The CPDT was calculated during the exponential phase of cell growth. It was determined from 
the growth curves of nCPs and aCPs of interest and was based on the assumption that during 
the exponential growth, relative growth rate remains constant, which allows the 
determination of CPDT with high precision.  
 
Ageing has a potential negative effect on a different aspect of cell division and growth. CPs 
harvested from patients of two different age groups (nCPs and aCPs) were thus compared to 
see if there is any significant decline in CPDT for cells of older origin (see Figure 33).  
Table 19: Results of the change in the cell density over the period of 8 days. In total six cell 
lines were used, three nCPs (CP2, CP16, CP21) and three aCPs (CP22, CP24 and CP25) For each 
cell line 3000 cells were seeded initially, and the change in cell number was monitored by 
measuring the new cell number at six different points of time (24, 48, 72, 96, 144 and 192 
hours) 
time 
(hours) CP2 CP16 CP21 CP22 CP24 CP25 
0 3000 3000 3000 3000 3000 3000 
24 3103 2169 -  -  3869 1735.251 
48 4675 5670 5402 3197 7475 4715.363 
72 5923 7734 3709 6624 8980 7387.566 
96 6675 9267 8771 4392 10930 8931.648 
144 7688 13187 12192 6053 13031 11224.54 
192 10351  - 14188 7889 15948 11443.19 
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Table 19 presents quantitative data obtained upon analyses of images (see Figure 33) 
collected over the period of eight days. Three thousand cells of each line aCPs (n=3) or nCPs 
(n=3) were seeded in 96-well plate and incubated at 37°C 5% CO₂ for 8 days to study potential 
variability in CPDT between two age groups.  
 
Figure 33: Representative images of the change in the density of nCPs and aCPs over the 
period of six days. Cells were stained and images were obtained at 24, 48, 72, 96 and 144 
hours after initial seeding. Original images (black background with light spots) are presented 
together with adjusted pictures (white background and black ellipses), generated using 
ImageJ Particle analyser plugin. Adult cardiac pericytes (aCPs), newborn cardiac pericytes 
(nCPs). 
Cellular densities of each individual cell lines were measured at six different time points and 
the resulting values were plotted against corresponding time to generate growth curves for 
each cell lines (see Figure 34 B). The results were then combined to generate an average 
growth curve for nCPs and aCPs (see Figure 34 A). The graphs were generated using Software 
GraphPad Prism version 7.0. 
The change in the cell number within given population with respect to time (equation 13)  was 
an exponential relationship, described by the first order kinetics law, where final  




Figure 34: Results for the nCPs and aCPs growth curves. The change in the total number of 
cells was monitored over the period of eight days at six different time points (24, 48, 72, 96, 
144 and 192 hours). 
A: Grouped growth curves of nCP (blue) and aCP (red) cell lines. The growth curve for nCPs 
was generated by combining data from CP2, CP16 and CP21, and for aCPs from CP22, CP24 
and CP25. Data are expressed as mean ±SEM (n=3) 
B: Six individual growth curves for each CP cell line. Three growth curves of nCPs (CP2, CP16 
and CP21) are indicated with blue shades; three growth curves of aCPs (CP22, CP24 and CP25) 
are indicated with red shades. 
Adult cardiac pericytes (aCPs), newborn cardiac pericytes (nCPs). 
concentration (3a) is equal to initial concentration (3b) times Euler’s number (e), to the power 
of: growth constant (k) times change in time (aka final time (4a) minus initial time (4b)). 




Figure 35: Average CPs cell population doubling times determined experimentally. Data are 
expressed as mean ±SEM (n=3). Blue colour indicates nCPs and red colour aCPs. No significant 
difference was identified between nCPs and aCPs (Mann-Whitney P>0.9999). Adult cardiac 
pericytes (aCPs), newborn cardiac pericytes (nCPs). 
Equation 13 
3a = 3b ∗ >c(defdg) 
Through the rearrangement of this equation (equation 13), the growth constant (equation 














To calculate CPDTs for each cell line, the initial and final time points of the growth curve were 
defined and applied to the formula described above (equation 15). For all cell lines tested, 
the information of the numbers of cells was available for 48 hours and 144 hours. These 
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values of cellular density were used with respect to time of measurement to calculate the 
CPDT for each cell line (see Table 19). In order to compare the results of CPDT calculated for 
nCPs and aCP, the average CPDT for each age group was determined and further analysed 
with Software GraphPad Prism version 7.0.  
The average CPDT was 98.1 and 100.2 hours for newborn and adult respectively (see Figure 
35). The Mann-Whitney test performed showed no significant difference between the CPDT 
of two age groups studied (P>0.9999). 
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 Clonogenic capacity 
The clonogenic capacity of neonatal CPs was reported before (Avolio, et al., 2015 (a)), so in 
order to complete the comparison between the age groups, adult cell line, CP24 was used for 
the clonogenic assay. This was a pilot study as no aCPs were used ever before for the 
clonogenic analyses.  
In the total 239 wells were seeded with 1 cell and one extra well was seeded with 100 cells as 
a positive control. The initial plan was to incubate cells for two weeks at 37°C 5%CO₂. 
However, the first two weeks of incubation, there were hardly seen any cells within the wells, 
the plates were incubated for an additional week. At the end of the third week, out of 239 
wells seeded, the colonies were seen in 7 out of 239 wells. However the control initially 
represented by 100 cells showed no cells after two weeks nor after three weeks of incubation, 
hence it was assumed that the experiment had failed and should be repeated in the future 
(see section 9.4)  
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Chapter 8  Results: antigenic characterization of cardiac pericyte 
derived VSM-like cells 
Pericytes were characterized before by their capability to transdifferentiate towards other 
cell types. The ability of CPs to switch to VSM-like phenotype had been tested and confirmed 
before (Avolio, et al., 2015 (a)).  
Similar experiments were performed in order to see if both nCPs and aCPs possess similar 
plasticity. CPs were seeded and expanded at P5 and after two weeks of exposure to 
differentiation media, the transdifferentiated cell-lines were studied in terms of marker 
expression, as was done for baseline CPs (see section 3.2). The potential variability in the 
SMC-marker expressions were analysed qualitatively. 
 Antigenic characterization of CP-derived VSM-like cells 
Six CPs (aCPs n=3 and nCPs n=3) were used to study the ability of pericytes to form VSMCs. 
The new mural phenotypes of the cell lines were extensively characterised in terms of antigen 
expression.  
 
Initially newborn and adult CP-derived VSMCs  were tested for canonical pericyte markers: 
NG2 and PDGFR-β (see Figure 36 A). Both of these markers are also often used as VSMCs 
markers as well, so could be alternatively defined as common mural markers. However, for 
the purpose of consistency, the categorisation used in section 3.2 was retained.  
Upon differentiation, cells of newborn and adult origin both had changed their morphology 
from spindle-shaped to more elongated (see Figure 36 and Figure 37). Also, the monolayer 
formed by CP-derived VSMCs of nCP and aCP origin appeared to be more organized when 
compared to baseline cells, based on the qualitative assessment of the cellular images under 
the microscope.  
The pattern of pericyte marker expression also changed for both NG2 and PDGFR-β (see 
Figure 36 A). While nCPs and aCPs expressed NG2, it was diminished upon transdifferentiation 
to VSM-like cells in both age groups. The expression of PDGFR- for both nCPs and aCPs also  




Figure 36: Immunofluorescent characterization of transdifferentiated nCPs and aCPs. The 
cells acquired VSM-like phenotype. 
A: Representative fluorescent images of neural glial antigen 2 (NG2) and platelet derived 
growth factor receptor beta (PDGFR-β) surface marker expression by nCPs and aCPs- derived 
VSM-like cells. Nuclei of the cells were stained with HOECHST (blue) and the protein of 
interest was visualized through binding of secondary antibody conjugated to Alexa Fluor 488 
dye (green). Scale bar: 100!". 
B: Representative fluorescent images of Ki67 marker expression by nCPs and aCPs- derived 
VSM-like cells. Nuclei of the cells were stained with HOECHST (blue) and the protein of 
interest was visualized through binding of secondary antibody conjugated to Alexa Fluor 488 
dye (green). Red arrows represent example of cells negative for marker tested and green 
arrow indicate positive cell. Scale bar: 100!". 
Adult cardiac pericytes (aCPs), newborn cardiac pericytes (nCPs), adult vascular smooth 
muscle (aVSM), newborn vascular smooth muscle cells (nVSM). 
altered following trans-differentiation and was consistent between the two age groups. 
However whether the positivity observed for nCP-derived VSM-like and a-CP derived VSM-
like cells is caused by the artefact or the alteration in the nature of protein expression is still 
to be investigated in the future. These results correlate with the ICC stainings of aortic SMC 
(see appendix 1) tested for expression of pericyte markers. However, it is important to 
address the fact that aortic SMC originating from the aorta, the largest vessel in the body, 
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while CPs possess more microvasculature like phenotype. Hence these can express variations 
in phenotypic behaviour and need to be compared with caution. 
VSMCs are more mature cell phenotype compared to CPs, with lesser proliferation potential, 
and cellular plasticity. This supports the result of the Ki67 staining, which is a nuclear 
proliferation factor (see Figure 36 B). This marker is normally associated both with 
proliferation and ribosomal RNA transcription, and so is also sometimes addressed as 
senescence marker (Bullwinkel, et al., 2006). 
The baseline cells of both aCP and nCP groups presented as populations of cells positive for 
Ki67 (see Figure 36 B). Upon transdifferentiation, the CP-derived VSM-like cells of both age 
groups were all negative for Ki67, supporting the idea of cells switching to more mature 
phenotype.  
 
The cells were then tested for multiple SMC markers: the synthetic, early non-specific 
contractile and contractile markers. First, the expression of synthetic SMC markers (see 
Figure 37 A) by members of both age groups were analysed. Two markers were used in total: 
α-non-muscle-myosin B (α-NMMyo2B) and α-RBP-1 for aCP- and nCP-derived VSM-like cells 
and the results were compared between two age groups. Baseline/undifferentiated nCPs and 
aCPs were used as controls to monitor the change in the phenotype of the cells.  
Based on qualitative assessment upon transdifferentiation, the expression pattern of α-
NMMyo2B had changed following phenotype switch and the relative fraction of cells that 
appeared positive for α-NMMyo2B had increased a lot. The expression of RBP-1, on the other 
hand, remained quite similar to the pattern observed at baseline phenotype. There was also 
found no major differences between CP-derived VSMs of the two age groups. Also, both 
synthetic SMC markers tested, CVFs and aortic SMC appeared to be positive, while CAECs 
appear to express RBP-1 at a lower level, and to be negative for NMMyo2B (see appendix 1). 
VSMCs can be sub-divided into synthetic and contractile phenotypes. While synthetic cells 
are more prevalent during embryonic development and associated with vasculogenesis (Gall, 
et al., 2010), the contractile phenotype predominates mostly in adult tissue and are 
responsible for vessel contraction (Owens, et al., 2004). In terms of regeneration it is  




Figure 37: Immunofluorescent characterization of differentiated phenotype: expression of 
smooth muscle cell markers. 
A: Representative fluorescent images of synthetic SMC markers expressions: Non-muscle 
myosin 2 B (NMMyo2B) and retinol-binding protein-1 (RBP-1). Both nCPs and aCPs are 
presented together with corresponding CP-derived VSM-like cells of both age groups. nCPs 
are indicated with blue colour and aCPs with red colour. Red arrows represent example of 
cells negative for marker tested and green arrow indicate positive cell. 
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B: Representative fluorescent images of early non-specific contractile SMC markers 
expressions: smooth muscle actin (SMA), α-calponin and transgelin. Both nCPs and aCPs are 
presented together with corresponding CP-derived VSM-like cells of both age groups. nCPs 
are indicated with blue colour and aCPs with red colour. Red arrows represent example of 
cells negative for marker tested and green arrow indicate positive cell. 
C: Representative fluorescent images of late specific contractile markers expressions: smooth 
muscle myosin heavy chain (SM-MHC2B) and α-smoothelin. Both nCPs and aCPs are 
presented together with corresponding CP-derived VSM-like cells of both age groups. nCPs 
are indicated with blue colour and aCPs with red colour. Red arrows represent example of 
cells negative for marker tested and green arrow indicate positive cell. 
Adult cardiac pericytes (aCPs), newborn cardiac pericytes (nCPs), adult vascular smooth 
muscle (aVSM), newborn vascular smooth muscle cells (nVSM). 
important for neovascularization of damaged tissue to involve the formation of contractile 
VSMC, rather than synthetic, with decreased cell proliferation (see Figure 36 B) and 
expression of contractile proteins (Beamish , et al., 2010), rather than synthetic proteins. 
In order to further investigate the nature of CP-derived VSM-like cells and compare them 
between two age groups, the expression of early contractile cell markers: α-SMA, α-calponin 
and Transgelin, were examined. As seen from stainings (see Figure 37 B), baseline CPs of both  
age groups occasionally presented only a small number of cells positive for early contractile 
cell markers. Upon transdifferentiation, the pattern of marker expression by both age groups 
had changed gradually, based on the qualitative assessment. VSM-like cells of both newborn 
and adult origin appeared to express all three markers homogeneously throughout cell 
population, with only a small proportion of cells infrequently presented as negative (see 
Figure 37 B). Interesting the expression of all three markers appeared to be present for lesser 
proportion of aortic SMCs, when observed under the microscope (see appendix 1).  
The last two markers tested were α-SM MHC2B and α-smoothelin, which were late 
contractile cell markers. While in VSMCs in vivo, both proteins are expressed as fibres or 
filaments (reviewed in (Rensen, et al., 2007)), neither α-SM MHC2B nor α-smoothelin appear 
to be expressed in baseline nCPs and aCPs in such way. Instead, CPs of both age groups only 
express α-smoothelin within nuclei, according to a qualitative assessment of ICC images (see  
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Figure 37 C). Upon transdifferentiation, the newly formed VSM-like cells showed a different 
signal pattern for late contractile cell marker stainings, and those transformations were 
consistent between nCPs and aCPs studied. In case of smoothelin, the localisation of signal 
had shifted from nuclei to cytosol; while SM-MHC2B, though was not often detected, 
appeared positive for a small fraction of cells within cultures of both age groups (see Figure 
37 C). However despite there appeared a change in the localisation of signal when observed 
with fluorescent the microscope, its patter suggests it is due to the background noise, rather 
than enhancement in protein expression.  
Generally, late contractile markers are expressed by SMCs in vivo and the expression of both 
α-SM-MHC2B and α-smoothelin is normally lost upon culturing in vitro (reviewed in (Rensen, 
et al., 2007)). This is also supported by the evidence obtained on aortic SMC staining for α-
SM MHC2B and α-smoothelin, both of which also appeared quite weak (see appendix 1). 
Hence the signals detected for both age groups of CP-derived VSMCs, when stained with anti- 
α-SM MHC2B or anti-α-smoothelin antibodies, were most probably associated with 
background noise, rather than filament expression. 
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Chapter 9 Discussion 
 General discussion  
In the past decade the number of individuals living with congenital and acquired heart 
conditions has been increasing gradually. Thanks to the novel surgical interventions the 
number of newborn and children undergoing successful palliative surgery for correction of 
CHD and becoming fit enough to a live normal healthy life constantly grow. However, children 
and adults with cardiovascular pathologies often require more than one operation and 
therefore could remain at a life-long risk of developing complications and event eventually 
progressing to HF. Hence the development of a novel therapy, which would be less invasive, 
not require repetitive interventions and promise better long-term prognosis is hence so 
anticipated. Stem cell-based tissue engineering is a fast-growing and expanding research field, 
aiming to create therapy capable of overcoming limitations such as the inability of the current 
graft to contribute to the growth of terminally differentiated host tissues. The ideal outcome 
of such therapy would be to induce regeneration of damaged tissue, rather than repair.  
 
The contribution of various pericyte sub-populations to tissue regeneration in vivo was 
previously reported by different research groups, including pre-clinical trials of CD146+ 
microvascular pericytes in dystrophin-deficient mouse model (Crisan, et al., 2008), and CD34+ 
SVPs in the mouse model of limb ischemia (Gubernator, et al., 2015) and CD34+ SVPs in the 
murine infarct heart model (Avolio, et al., 2015 (b)). Based on those results, pericytes despite 
being so heterogeneous population could serve as a powerful tool in bioengineering in the 
future. Upon expansion in vitro, these cells are assumed to contributing to tissue 
neovascularization and regeneration in vivo, after they are re-introduced into the host. 
After SVPs were reported to possess functional ability to contribute towards regeneration of 
infarcted mouse heart tissue (Katare, et al., 2011) a similar populations of cells were 
discovered in heart tissue leftovers of newborn patients undergoing palliative surgery for 
correction of CHD (Avolio, et al., 2015 (a)). These CPs were suggested to be theoretically more 
suitable for heart regeneration, compared to SVPs, due to their parenchymal origin. While 
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the results on the characterisation of neonatal CPs, provided much hope, there were other 
considerations.  
Previous studies have indicated that the senescent nature of progenitor cells could be 
reversed at least partially (Avolio, et al., 2014), and allowed to look on the issue of pathologies 
associated terminally differentiated organ, such as heart, at a new angle.  
Unlike paediatric CPs, CPs isolated from the adult heart were never been previously studied 
to the author’s knowledge. Inspired by the regenerative potential, reported for neonatal CPs 
originating from CHD patients, in conjunction with the ability of these cells to 
transdifferentiate to VSMCs, current project extensively investigated antigenic and functional 
properties of aCP together with nCPs to determine if ageing significantly affects properties 
and plasticity of these cells. This may have important implications not only for replacement 
approaches of regenerative medicine but also for a better understanding of the influence of 
ageing on resident cell populations and their related functions. The implications to CHD are 
also important because the hearts of these patients are subjected to particular stress, 
included repeated operations and hemodynamic load, which could accelerate the senescence 
by different mechanisms.  
 
Initially, CPs were isolated based on CD31-negative/CD34-positive magnetic sorting from both 
newborn and adult cardiac tissues. Upon expansion, both nCPs and aCPs appeared to present 
similar spindle-shaped morphology, which is a characteristic feature of mural cells, including 
pericytes.  
 
After isolated cells got expanded in vitro, they were antigenically characterised. The 
expression of multiple sets of markers, associated with various cell types residential in the 
vessels, were tested and compared between nCPs and aCPs. Based on results obtained the 
antigenic profiles of nCPs and aCPs were similar, with no major exceptions or outliers. These 
antigenic profiles also correlated well with previous finding on neonatal CPs (Avolio, et al., 
2015 (a)). This was a promising beginning, as cells originating from adult patients are usually 
associated with a decrease in cellular plasticity and potency accomplished by phenotypic 
change when compared to younger cells.  
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The characterization of baseline phenotype involved three cell lines per group, nCPs: CP2, 
CP16, and CP21; and aCPs: CP22, CP24, and CP25. As expected both age groups were positive 
for canonic pericyte markers NG2 and PDGFR-β. Although CPs were initially isolated based on 
CD34 positive selection, the expression of this marker was lost upon co-culturing and by 
reaching P5 was non-detectable by ICC staining. 
The expression of CD146 marker, associated with particular pericyte sub-population 
residential in the heart (Chen, et al., 2015), was not detected in either nCPs nor aCPs, which 
correlated well with previous studies of CD34-positive neonatal CPs (Avolio, et al., 2015 (a)). 
In terms of CD146 expression CPs (Avolio, et al., 2015 (a)) similarly to SVPs (Campagnolo, et 
al., 2010) lack expression of this marker. And while for SVPs originating from large vessel such 
behaviour correlates well with current understanding of APCs antigenic profile (Campagnolo, 
et al., 2010), as the expression of CD146 is only associated with microvascular pericytes (Chen, 
et al., 2015). However based on histological staining neonatal CPs were both located within 
cardiac microvasculature and large vessels (Avolio, et al., 2015 (a)). Another recent study 
suggested that CD146 expressing cardiac residential progenitor cells may contribute towards 
organ fibrosis followng damage through maturation towards myofibroblast lineage 
(Kramann, et al., 2015). As a consequnce the pericytes lacking CD146 such as CPs could simply 
belong to a different pericyte subtype with so my present variable molecular and funtional 
characteristics, which need to be further asseseed and compared in details. More resent 
paper however had suggested that the decline in the expresion of CD146 by human umbilival 
cord blood-derived mesenchymal stem cells is associated with senescent phenotype (Jin Jin, 
et al., 2016). Whether this finding is relevant to CPs is however yet to de discovered.  
The results of stem cell markers stainings (SOX-2, OCT-,4 and NANOG) implying high plasticity 
of both age groups. However, the staining of more differentiated commercially available cell 
lines used as controls, also suggested relatively high fraction positive cells, leaving the open 
question of reliability of results obtained with these antibodies (see appendix 1).  
In terms of progenitor cell markers tested, both nCPs and aCPs showed similar patterns of 
expression and appeared positive. The intensity of GATA4 suggesting high similarity and 
immature cardiac phenotype. On the other hand the despite cells also appeared positive for 
PDGFR-a, signal intensity was not very strong. This could have an alternative explanation, as 
there have been reports associating the activation of PDGFR-a in vascular cells with tissue 
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fibrosis (Iwayama, et al., 2015). Perhaps it could be speculated that minor expression of 
PDGFR-a by pericytes has lesser potential to participate in fibrosis. 
The difference in the endothelial cell marker expression between the two age groups was not 
significant. However there were identified small fractions of CD31 and VE-Cadherin positive 
cells within nCPs and aCPs. Though originally CPs were extracted from tissue based on CD31 
negative sorting after in vitro expansion some cells acquired endothelial cell marker 
expression. It also remains to investigate if there was a co-expression of CD31 and VE-
Cadherin by these cells. The level of CD31 expression was just above 5% for both nCPs and 
aCPs, so further investigation with larger sample group is necessary to make an assumption 
on whether the positivity comes from heterogenous nature of cells or another source yet to 
be identified As for the reasons though the risk of contamination cannot be completely 
excluded, it is unlikely to cause as the method of cell isolation is believed to be very effective 
and should not lead to such level of impurity. On contrary previous work on neonatal CPs, 
failed to produce CP-derived ECs (Avolio, et al., 2015 (a)) suggesting their distinctive lineages 
and questioning whether CPs can actually acquire endothelial cell phenotype.  
A type III intermediate filament vimentin is also often recognized as a pericyte marker and 
was found to be expressed extensively throughout all CPs tested. The expression of ECM 
components collagen type 1 and fibronectin by both age groups correlated and implied to be 
produced and secreted. 
The results of qualitative and quantitative analysis of ICC-IF implied that all nCPs and aCPs 
studied, represented a population of mural cells, yet all distinct from VSMCs. Hence it could 
be concluded that both nCPs and aCPs presenting samples of different age groups represent 
very similar populations of cardiac residential mural cells in terms of antigenic profile based 
on markers tested.  
 
The expression of three surface markers was further investigated. The two pericyte markers 
PDGFR-β and NG2 together with PDGFR-a were further studied with western blotting. It was 
a pilot study to see how the western blotting would resemble the results of ICC-IF.  
While the PDGFR-β ICC staining appeared strong and consistent for all CP cell lines used, the 
NG2 staining, on the other hand, appeared weaker and required a longer time of exposure 
for the images to be obtained. In order to confirm the ICC signal originated from the protein 
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expression and not the background noise, western blotting was performed. PDGFR-β and NG2 
markers were tested to see the relative amount of protein expression. As this was only a pilot 
experiment and due to lack of samples two paediatric CPs (CP5 and CP21) and one aCP (CP24) 
were used, no conclusion regarding age-dependent variation in the marker expression was 
made from this test. Unlike all other experiments, one of the two paediatric samples the CP5 
cell line was originated from the infant age group (1-12 months), due to a shortage of clinical 
samples. From these experiments, the expression of NG2 appeared to be quite week, while 
consistent between all three cell lines tested; while the PDGFR-β expression results were 
much more diverse amongst cell lines. Two out of three CP lines showed a very high level of 
PDGFR-β protein expression (child CP5 and adult CP24), despite originating from different age 
groups. The newborn CP21 presented with much dimmer band suggesting a lower level of 
protein expression. For all three cell lines studied, bands presenting the housekeeping gene 
β-Tubulin appeared of the same size on the membrane. This implied the amount of protein 
loaded was consistent for all three cell lines used, and hence any variation in band size 
corresponded to the actual variation in the level of protein produced between cell lines. Such 
variation in PDFGR-β protein expression appeared to be present between two paediatric CPs 
cell lines tested, while single aCP cell line (CP24) tested appeared to express it at higher level 
than nCPs CP21. These results could indicate the heterogeneity of pericytes and not dictated 
by ageing.  
The PDGFR-α was another marker further investigated with western blotting. Its expression 
was initially detected by ICC staining, but its signal was quite weak based on the qualitative 
assessment. Unlike with PDGFR-β and NG2, it was challenging to interpret the staining for 
anti-PDGFR-α, due to weak fluorescent of the signal observed complicated by the presence 
background noise. According to western blotting, only the CP5 samples had shown strong 
recognition by the antibody. The newborn CP21 did not present any band on the membrane, 
despite quite long exposure, while adult CP24 expressed single week band seen on the 
membrane, suggesting the presence of small amount of protein epitope containing protein.  
Despite no conclusion was derived from western blotting, these results found no correlation 
between the amount protein expression and ageing.  
Overall the results of the western blotting did not fully support the findings of the ICC-IF. Only 
one cell line per each age group as used, and perhaps in order to validate the finding at least 
three samples per each age group need to be used. Furthermore all three markers tested 
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were surface antigens, hence alternative approach such as FACS can be applied to determined 
reliability of ICC-IF and western blotting. 
 
 
ELISA assay was then conducted on CP-derived CMs in order to study its composition in terms 
of the presence of pro-angiogenic GFs. CMs were obtained from nCPs (CP2, CP16, and CP21) 
and aCPs (CP22, CP24, and CP25) which were analysed for the secretion of Ang-1, Ang-2 and 
VEGF. Previously neonatal CPs were found to secrete GF, which contribute to angiogenesis, 
including the ones listed above (Avolio, et al., 2015 (a)). Results of current work indicated that 
there was no significant difference in the amount of Ang-1, Ang-2 and VEGF secreted by nCPs 
and aCPs, despite all three factors were found to be secreted by the cells. Therefore implying 
that at least in terms of these GFs tested, no age-dependent variation occurred. While both 
age groups were found to secrete three essential pro-angiogenic factors, the paracrine pro-
angiogenic ability of CPs to contribute to vessel formation and growth could be also attributed 
to other GFs untested in this research. In the future, it is important to perform more detailed 
research on the composition of aCP-derived CM for other GFs and cytokine mediators. 
 
The next step was to test the ability of CPs to participate in angiogenesis. The enhancement 
of EC-network formation by CPs and other pericytes were reported before (Avolio, et al., 2015 
(a)). In vivo pericytes are situated in close proximity to ECs supporting those externally and 
such organisation is believed to be key to microvessels homeostasis (Armulik, et al., 2011). In 
order to test whether there is an association between age and the ability of pericytes to 
contribute to angiogenesis, two separate experiments were performed.  
First CPs were co-cultured with CAECs to observe how CPs of different age would contribute 
to network formation and stability. Upon co-culture and assessment of cellular tubes formed 
there was found no significant difference between two age groups in terms of length of 
networks formed on matrigel after 8 hours of incubation. However, it is also important to 
highlight, that only the aCPs significantly increased the length of networks formed by CAECs. 
The change was however very similar to that in nCPs and more cases need to be studied to 
reach sufficient power. 
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Transplanted stem cells do not appear to survive long in host tissues. Yet many trials reported 
significant improvement of the condition following stem cell therapy, which implies the 
therapeutic effect to be attributed to the action of paracrine mediators of those cells 
(Gnecchi, et al., 2008). Based on the results of ELISA the CMs of both nCPs and aCPs contains 
a detectable amount of major pro-angiogenic GFs, so the ability of CM to enhance network 
formation by CAECs was further investigated. It was suggested that upon incubation of CAECs 
with CP-derived CMs, there would be an increase in the total network formed. Despite the 
only aCPs appeared to significantly increase total network length when compared to UCM 
media, the difference between nCPs and aCPs were not significant. However similarly to 
matrigel co-culture, the difference in between nCPs and aCPs were quite small and further 
studies are necessary.  
By now it can only be stated that aCPs do contribute to network formation both through 
paracrine action and direct contact. Furthermore, there are no bases to assume an ageing-
induced decrease in pro-angiogenic activity of CPs. 
 
The self-renewal capacity is attributed to progenitor cells and is subjected to age-related 
changes. The CPDT was calculated for both age groups and compared to see whether CPs 
loose self-renewal capacity during ageing. Based on the results of six cell lines studied (nCPs: 
CP2, CP16, CP21, and aCPs: CP22, CP24, and CP25) the difference was not found to be 
significant between two age groups. 
The FACS single cell sorting was used as a clonogenic capacity assay to study the 
heterogeneity of individual adult cell line (CP24). In a similar experiment performed on 
neonatal sample, it was indicated 10-11% of cells possess clonogenic capacity (Avolio, et al., 
2015 (a)). Unfortunately, the clonogenic assay attempted for CP24 adult cell line during this 
project failed and due to lack of sufficient time was not repeated, so the reason of failure is 
yet to be determined. Though this was the first study of the aCPs clonogenic capacity, the 
reason behind poor results could be either due to the choice of the particular cell line as well 
as the method used. The CP24 cell line originated from 54 year old patient, was the oldest cell 
line available. Also the ICC-IF staining of endothelial cell markers this showed a distinctively 
higher level of CD31 and VE-Cadherin (results not shown) expression. 
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Contrary as also discussed later in the limitations (section 9.3), FACS is relatively vigorous 
technique subjecting cells to a lot of stress, which does not promote cell survival and 
proliferation, but in fact may have the opposite effect. Due to the lack of time, this experiment 
could not be repeated using another cell line, which leaves the question of the clonogenic 
capacity of aCPs to be addressed in the future research.  
 
Finally, nCPs and aCPs were compared in term of cellular plasticity. Previously it was reported 
that the non-mature VSMCs derived from human pluripotent stem cells undergo maturation 
and the resulting synthetic or contractile phenotype is determined by PDGF-BB or TGF-β 
supplementing differentiation media respectively (Wanjare, et al., 2013). In the original paper 
characterising neonatal CPs, the cells were exposed to differentiation media supplemented 
with 20ng/ml PDGF-BB (Avolio, et al., 2015 (a)). However current research used transduction 
media supplemented with TGF-β, which showed a higher success rate for differentiation of 
CPs towards VSM-like lineage based on the optimization experiments performed in the lab 
(results not shown). Furthermore TGF- β was suggested to promote the transition of VSMCs 
towards more contractile phenotype (Hirsch, et al., 1998).  
Upon exposed to differentiation media all cell lines tested underwent transdifferentiation to 
VSMC-like phenotype. For both age groups, the morphology of cells had changed to become 
more elongated. Baseline aCP and nCPs were positive for α-NMMYO2B and RBP-1, both of 
which were synthetic SMC-markers. Following the transition to VSM-like phenotype both 
nCPs and aCPs the expression three synthetic markers were enhanced gradually. 
The expressions of three early contractile VSMC-markers: α-SMA, Transgelin and α-calponin 
by nCP- and aCP-derived VSM-like cells appeared quite strong, while at the baseline level the 
expression would be detected rarely.  
There were low levels of detection for the late contractile VSMC markers α-SMMHC2B and α-
smoothelin in CP-derived VSMCs as well as baseline cells. For the differentiated cells, the 
signals detected was attributed to the background noise rather than the elevation in the level 
of protein expression.  
Synthetic and contractile VSMC markers tested expression was similar between two age 
groups. Furthermore, the prevalence of synthetic phenotype marker expression is at least 
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partly attributed in vitro conditions, where SMCs shift towards synthetic phenotype, 
synthesizing and secreting ECM-components (reviewed in (Rensen, et al., 2007)).  
Based on these results, CP of both age groups are capable of transition towards more mature 
cell type and upon transdifferentiation to VSM-like type acquire the expression of markers 
associated with true VSMCs. Whether these cells also resemble the functional profile of 
VSMCs remains under investigation, and was not involved in this project. 
Overall the results of the current research suggest that the CPs, despite the age of origin, 
possess very similar characteristics in terms of antigenic, molecular and functional properties 
based on the experiments performed. Adult cell lines appear to retain their both antigenic 
and functional potential and despite original hypothesis were capable of transdifferentiation 
to VSMCs like nCPs.   




Previously only nCPs were described, however for the first time we had managed to isolate 
and purify CPs from the adult tissues. This was a pilot study and involved only a small number 
of samples per group (n=3). Despite the aim of this work was to compare CPs isolate from 
newborn and adult patients, the senescence associated with both age groups was not 
investigated as part of this work 
Based on the antigenic, molecular and functional analyses aCPs appeared to resemble quite 
many features of the younger cells obtained from paediatric subjects (nCPs). Importantly 
adult cells also presented high pro-angiogenic capacity. Furthermore, the phenotypic switch 
of CPs to VSM-like cells and seems not to be diminished by the age.  
Yet both nCPs and aCPs were only isolated during TOF open chest surgeries. This created a 
hypoxic and stressful conditions for cells and might have promoted cellular senescence. 
Hence even though the nCPs did not appear superiors when compared to aCPs, the results 
are only relevant to CPs originating from patients with congenital heart pathologies and so 
cannot be extrapolated neither to patients with acquired heart pathologies, nor to CPs 
isolated from healthy hearts. 
The single adult CP line subjected to single cell sorting failed to show clonogenic capacity, for 
the reasons to be discovered in the future. As during this experiment no nCP was used as a 
control, it is impossible yet to say what was the cause of failure.  
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 Limitations and future challenges 
This work was based on the characterisation and comparison of CPs isolated from newborn 
and adult patients with CHD, and investigation the potential future application of these cells 
for the therapeutic purpose including stimulation of residential cells or transplantation. The 
isolated was based on sequential separation using CD31-/CD34+ magnetic sorting. Initially 
the CD31 positive cells were depleted following by isolation of CD34 target cells. However 
previously when SVPs were isolated using the same principle, the purity of cell lines on 
average did not exceed 70% (Campagnolo, et al., 2010). As a result the phenotypic and 
functional characteristics of remaining 30% of the cells is still unclear and need to be further 
addressed in the future. 
The cellular environment plays a crucial role in cellular homeostasis. Harsh changes in the 
parenchymal environment such as pre-existing pathological condition can trigger both 
epigenetic and gene expression changes, influencing cell phenotype (Sun, et al., 2014). This 
means that the same cell types will present different phenotypes due to underlying 
pathologies and pre-existing conditions that the individuals have. 
The same cell types derived from patients with variable pre-existing or underlying pathologies 
may present significant variation in phenotypes in vitro. This means that cells obtained from 
CHD patients may phenotypically and functionally different from cells obtained from a 
healthy individual, or individual suffering from acute myocardial damage.  
Samples used in this study were received as part of an original project designed towards the 
investigation of CPs for a possible application for CHD correction (Avolio, et al., 2015 (a)). In 
the current study, there was slight variation in the passage number of cell lines used for 
experiments, and both P5 or P6 were used together assuming no significant variation would 
be presented in cellular behaviour. This could potentially arise the inconsistency in the level 
of certain marker expression, especially proliferation/stem cell markers such as OCT4, OCT4, 
and NANOG. Unfortunately, this limitation was unavoidable due to a shortage of cell lines 
available.  
There was noted a variation in the intensity of the fluorescent signal, possibly due to 
fluctuation in the level of protein expression amongst different cells. This is a common 
limitation for ICC and further analysis with the more quantitative technique was desirable. 
Hence as described in section 4.2 wester blotting was used to assess the relative quantity of 
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three markers NG2, PDGFR-β, and PDGFR-α. However, this was a pilot study and a limited 
number of cell lines were used. In the future, other marker expression level should be studied, 
and potentially other techniques such as flow cytometry or real-time quantitative PCR can be 
applied as semi-quantitative techniques. In addition, the limited availability of such precious 
cells did not allow to perform stem cell marker staining at a lower P (eg P3), which would 
normally be desirable to identify any potential change in the patter of stemness marker 
expression over cell line ageing. 
During this study we failed to isolate adult clonogenic cells, for the reasons to be determined 
in the future. The possible explanation of current failure could as well be the choice of 
technique. During single cell sorting performed by FACS cells are subjected to a lot of stress, 
including separation and radiation before eventually being left alone in the well, where those 
are expected to generate clones. Such conditions do not promote cell survival and 
proliferation but on contrary lack of cell communication can trigger cellular senescence and 
apoptosis, so perhaps in the future a different approach should be used to study aCP 
clonogenicity. 
Another important limitation included the number of samples, as the total of three cell lines 
were used in most of the experiments per each age group unless otherwise stated. All of the 
cardiac sample, used for CP isolation, were collected during open chest operation performed 
on the human heart. Both newborn under the age of 30 days and adults over the age of 14 
years, do not often undergo a CHD-related operation. This is because the baby may be too 
weak during their first weeks of life and cannot undergo an invasive surgical operation. 
Furthermore, for individuals with severe complications, who require surgical intervention 
shortly after birth, tissue samples cannot always be obtained. In addition, tissue leftovers are 
often too small and do not yield sufficient cellular amount for expansion. In the case of adult 
patients, there are other issues: as mentioned before, adults do not undergo surgery for 
correction of CHD as often as children do. Also, for adults suffering from CHD, the most 
common operation involves replacement of semilunar valve, which does not include 
atrial/ventricular biopsies and so no cells can be obtained for research. The range of age 
studied could be too short to appreciate differences between groups, and hence would be 
interesting to extend the studies to later stages of the life. If no difference is found, this could 
indicate that pericytes are resistant to the process of senescence. 
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Another limitation arose from the fact that the cells used in this study were not distinct based 
on the chamber of origin. It was reported before that the atrial and ventricular cardiac 
progenitor cells exhibit variation in both marker expression and paracrine-mediators (Dixit, 
et al., 2017). For the newborn age group, two cell lines were originating from RA and one from 
RV, while for aCPs two were of RV-origin and one from RA. In the future with more samples 
studied, the further investigation of the potential functional variation between CPs from 
difference location would be desired.  
Furthermore to complete the comparison of newborn and adult cells, in the future the 
expression of senescence-associated markers such as p16INK4a or p53 should be performed. 
This will then enable us to conclude if aCPs truly resemble features of nCPs and are resistant 
to senescence.  
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 Future challenges  
Human pericytes extracted from the saphenous vein were already tested by our team in small 
animal models (Avolio, et al., 2015 (b)) (Gubernator, et al., 2015) (Katare, et al., 2011) 
(Campagnolo, et al., 2010), however before entering the clinics, pericytes need to be tested 
in large animal models of cardiovascular disease. Porcine presents a good animal model of 
human cardiovascular disease, as genetics, metabolism, and lifestyle are more comparable to 
humans than the small animal models including mice and rats (reviewed in (Liao, et al., 2017)). 
However, the immune rejection occurring to human cells implanted in immune-competent 
swine affects the feasibility of these pre-clinical studies. In order to overcome this obstacle, 
Professor Madeddu and his team have recently adopted an allogeneic approach, testing the 
safety and therapeutic efficacy of swine-derived APCs in a swine model of re-perfused acute 
myocardial infarction (Alvino, et al., 2018). The in vitro evaluation of human paediatric CPs 
appears a safe option, hence the preclinical testing of pericyte alone or pericyte-enriched 
grafts for correction of cardiovascular disease such as CHD in a porcine animal model is 
essential to evaluate the long-term mechanism of remodelling following cell/prosthesis 
implantation. Professors Madeddu and Professor Caputo are currently conducting a 
preclinical study to evaluate the therapeutic efficacy of vascular grafts repopulated with 
swine CPs in a swine model of CHD requiring the replacement of the right pulmonary artery. 
The use of swine CPs, phenotypically and functionally similar to the human cells, provides a 
safer option for testing in swine, reducing the occurrence of immune rejection. Once the pre-
clinical trial shows beneficial outcomes, the human cells could be proposed for application in 
patients with TOF, and a similar approach could be used to treat other CHD, myocardial 
infarction and other heart pathologies. In this setting, our current work provides an essential 
investigation on aCPs for future applications. The aCPs were be tested in parallel with nCPs to 
assess any difference between the two age groups arising as a result of older cell age. 
This initial study has been performed with a limited number of cell lines due to the small 
number of patients recruited and the scarce availability of surgical leftovers. However, the 
current research will be replicated with additional cell lines as soon as they will be available. 
This will help to increase the sample number allow more robust statistical analyses to better 
highlight any differences between the two age groups. Moreover, we plan to isolate the CPs 
from ischemic adult hearts, as the ischemic environment itself can affect the functional 
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properties of cells despite their age of origin, as previously published by the team with regards 
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Additional cell lines used in this study 
Table A1: List of commercially available cardiac residential cell used during current study. 
Aortic SMCs: human aortic smooth muscle cells, CAECs: human coronary artery endothelial 
cells, CVFs: human cardiac ventricular fibroblasts 
cell line supplier code 
aortSMCs PromoCell C-12533 
CAECs PromoCell C-12221 
CVFs Lonza CC-2904 
 
Most work was performed using CPs, though some experiments required other cardiac 
residential cells to use as positive and negative controls for the markers tested. These cells 
(see Table A1) were used to compare the results of antigenic phenotype of nCPs and aCPs to 
the phenotype commercially available cardiac cells (see figures A1-A7). 
The immunocytochemical staining of these cells was of antibody control purpose and did not 
carry any research purpose. Hence the results of antigenic characterization of these cell were 




Figure A1: Immunofluorescent characterization of 
perivascular/ mesenchymal markers by aortic 
SMCs, CAECs and CVFs. 
A: Representative fluorescent images of NG2 and 
PDGFR-ß surface marker expression by aortic SMCs, 
CAECs and CVFs. 
B: Representative fluorescent images of CD34 and 
CD146 surface marker expression by aortic SMCs, 
CAECs and CVFs.  
Red arrows indicate example of cells negative for 
marker tested and green arrow indicate positive 
cell. Nuclei of the cells were stained with HOECHST 
(blue) and the protein of interest was visualized 
through binding of secondary antibody conjugated 
to Alexa Fluor 488 dye (green). 






Figure A3: Immunofluorescent characterization of 
stemness markers expression by aortic SMCs, CAECs 
and CVFs. 
Representative fluorescent images of SOX2, OCT4 and 
NANOG expression by aortic SMCs, CAECs and CVFs. 
Nuclei of the cells were stained with HOECHST (blue) 
and the protein of interest was visualized through 
binding of secondary antibody conjugated to Alexa 
Fluor 488 dye (green), however for better 
visualization, the colour was changed from green to 
yellow using ImageJ software. 
Scale bar: 50!" 
Figure A2: Immunofluorescent characterization of 
type 3 intermediate filament expression by aortic 
SMCs, CAECs and CVFs. 
A: Representative fluorescent images of vimentin 
expression. Nuclei of the cells were stained with 
HOECHST (blue) and the protein of interest was 
visualized through binding of secondary antibody 
conjugated to Alexa Fluor 488 dye (green). 
Scale bar: 100!" 
Red arrows indicate example of cells negative for marker tested 






Figure A4: Immunofluorescent characterization of 
progenitor cell marker expression by aortic SMCs, 
CAECs and CVFs. 
A: Representative fluorescent images of GATA4 and 
PDGFR-α marker expression. Nuclei of the cells 
were stained with HOECHST (blue) and the protein 
of interest was visualized through binding of 
secondary antibody conjugated to Alexa Fluor 488 
dye (green). 
Scale bar: 100!" 
Figure A5: Immunofluorescent characterization of 
endothelial cell marker expression by aortic 
SMCs, CAECs and CVFs. 
Representative fluorescent images of CD31 and VE-
Cadherin marker expression. Nuclei of the cells 
were stained with . Nuclei of the cells were stained 
with HOECHST (blue) and the protein of interest 
was visualized through binding of secondary 
antibody conjugated to Alexa Fluor 488 dye (green). 
Scale bar: 100!"  
Red arrows indicate example of cells negative for marker tested 






Figure A6: Immunofluorescent 
characterization of extracellular matrix 
proteins expressions aortic SMCs, CAECs 
and CVFs. 
Representative fluorescent images of 
intracellular and extracellular expression 
of collagen type I and fibronectin. Nuclei 
of the cells were stained with HOECHST 
(blue) and the protein of interest was 
visualized through binding of secondary 
antibody conjugated to Alexa Fluor 488 
dye (green). 
Red arrows present example of 
cells negative for marker tested and 
green arrow indicate positive cell. 










A: Fluorescent microscopy of aortic SMCs, CVFs and CAECs for the 
expression of synthetic SMC markers the non-muscle myosin 2 B 
(NMMyo2B) and retinol-binding protein-1 (RBP-1). Scale bar: 100µm 
B: Fluorescent microscopy of aortic SMCs, CVFs and CAECs for the 
expression of early non-specific contractile proteins the smooth 
muscle actin (SMA) and α-calponin. Scale bar: 100µm 
C: Fluorescent microscopy of aortic SMCs, CVFs and CAECs for the 
expression of late specific contractile markers the smooth muscle 








Markers excluded  
This appendix includes the two markers which were excluded from the original panel. The 
fibroblast surface protein -1 (FSP-1) and desmin (see figure A8), were both initially used in the 
antigenic characterization, however the results of these staining were not conclusive and 
hence were not presented in the result section of the thesis.  
FSP-1 
The FSP-1 protein was suggested as a marker of fibroblast cells. The anti-FSP-1 mouse 
polyclonal antibody (Abcam-ab11333) showed strong recognition in all cells tested (see figure 
A8). Based on information provided in the manufacturers datasheet the antibody was raised 
against S100 calcium-binding protein A4 (S100A4), which would be present on a wide range 
of cells, and not fibroblasts exclusively (Kong, et al., 2013). Hence as the experiment failed to 
identify cell line negative for what was claimed to be FSP-1 protein, the results were excluded 
from the discussion. 
Desmin 
Desmin is an important component of cytoskeleton mainly found in striated muscle cells, and 
is involved in sarcomere formation and function (Kim, 1996). As a component of sarcomere it 
was expected to be positive in aortic SMC, which belong to VSMC population. However the 
anti-Desmin mouse monoclonal antibody (Santa Cruz SC-23879) failed to detect any 
expressed protein remaining the question of reliability of this antibody to be addressed in the 






Figure A8: Immunofluorescent characterization of the expression of FSP-1 and desmin by cardiac 
residential cells. 
Representative fluorescent images of intracellular and extracellular expression of FSP-1 and desmin. Nuclei 
of the cells were stained with HOECHST (blue) and the protein of interest was visualized through binding of 
secondary antibody conjugated to TRITC/Rhodamine (red )and Alexa Fluor 488 dye (green). 
Red arrows indicate examples of cells negative for marker tested and green arrow indicate positive cell. 
 
 
